Document:

EX-10.1

 Exhibit 10.1 

FIRST AMENDMENT TO LEASE 

This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of the 29th day of August, 2018, by and
between HCP OYSTER POINT III LLC, a Delaware limited liability company (“Landlord”), and GLOBAL BLOOD THERAPEUTICS, INC., a Delaware corporation (“Tenant”). 

R E C I T A L S : 

A. Landlord and Tenant entered into that certain Lease dated March 17, 2017 (the “Lease”), whereby Landlord leases to
Tenant and Tenant leases from Landlord those certain premises consisting of a total of approximately 67,185 rentable square feet of space (the “Original Premises”) located on the second (2nd) and third (3rd) floors of that certain building located at 171 Oyster Point Boulevard, South San Francisco, California 94080 (the
“Original Building”). 
 B. Landlord and Tenant desire to relocate the leased premises from the Original Premises to
that certain space consisting of approximately 164,150 rentable square feet of space (the “Substitute Premises”) comprising the entirety of the building located at 181 Oyster Point Boulevard, South San Francisco, California
94080 (the “Substitute Building”), as delineated on Exhibit A attached hereto and made a part hereof, and to make other modifications to the Lease, and in connection therewith, Landlord
and Tenant desire to amend the Lease as hereinafter provided. 
 A G R E E M E N
T : 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.
Capitalized Terms. All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this First Amendment. 

2. Original Premises. 

2.1 In General. Landlord and Tenant hereby acknowledge and agree that Tenant may continue to occupy the Original Premises on all
of the terms of the Lease (except, following the Substitute Premises Commencement Date, the obligation to pay Base Rent and Direct Expenses with respect thereto, subject to the terms below) until the date (the “Surrender Date”)
which is sixty (60) days following the Substitute Premises Commencement Date (as that term is defined in Section 3.1 below), and notwithstanding any provision to the contrary contained in the Lease, Tenant shall quit
and surrender and deliver exclusive possession to Landlord of the Original Premises in accordance with the terms of the Lease as if the Lease had terminated. Notwithstanding the foregoing, if the Substitute Premises Commencement Date

  

					
		  		  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
occurs prior to Landlord’s delivery of the Substitute Premises in the required condition due to Tenant Delay, at Tenant’s request, the commencement of the sixty (60) day period and
the Surrender Date shall be delayed by up to one (1) day for each such day of delay (not to exceed sixty (60) days), and Tenant may continue to occupy the Original Premises during such interim period on all of the terms of the Lease
(including the obligation to pay Base Rent, Direct Expenses and Additional TI Allowance Payments with respect thereto). Subject to the foregoing, effective as of the Substitute Premises Commencement Date, Tenant’s lease of the Original Premises
shall automatically terminate and be of no further force and effect, except those obligations of Tenant set forth in the Lease, as amended hereby, which relate to the term of Tenant’s lease of the Original Premises (as modified above) and/or
which specifically survive the expiration or earlier termination of Tenant’s lease of the Original Premises, including, without limitation, the payment by Tenant of all amounts owed by Tenant under the Lease, as amended, with respect to the
Original Premises through and including the Substitute Premises Commencement Date (collectively, the “Survival Obligations”); provided, however, notwithstanding anything to the contrary herein, subject to the terms of
Section 2.3 below or pursuant to this Section 2.1 above, Tenant shall have no obligation to pay Base Rent or Direct Expenses with respect to the Original Premises after the Substitute Premises Commencement
Date. Effective as of the day immediately following the Substitute Premises Commencement Date, the Original Premises shall no longer be a part of the “Premises” and, effective as of the Substitute Premises Commencement Date, the term
“Premises” shall refer solely to the Substitute Premises and the term “Building” shall refer solely to the Substitute Building, and all references to the Lease Commencement Date, as to the Substitute Premises, shall mean the
Substitute Premises Commencement Date. In addition, Tenant’s termination rights under Sections 11 and 13 of the Lease shall apply with respect to the Substitute Premises commencing on the date of this First Amendment. 

2.2 Condition of Original Premises. Tenant acknowledges that Tenant has been and is in occupancy of the Original Premises
pursuant to the Lease, and is fully aware of the condition of the Original Premises. In addition, except for Landlord’s ongoing repair and restoration obligations expressly set forth in the Lease, Tenant shall continue to accept the Original
Premises in its “as is” condition, and Landlord shall not be obligated to provide or pay for any improvements or alterations to the Original Premises. Tenant also acknowledges that, except as may be expressly set forth in the Lease,
neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Original Premises, the Building, or the Project or with respect to the suitability of the same for the conduct of Tenant’s
business. 
 2.3 Surrender of Original Premises. Effective as of the Surrender Date, Tenant hereby agrees to vacate the
Original Premises and surrender and deliver exclusive possession of the Original Premises to Landlord on or before the Surrender Date in accordance with the provisions of the Lease and thereafter, Tenant shall have no further obligations with
respect to the Original Premises, except with respect to the Survival Obligations. Tenant hereby agrees to endeavor to decommission (the “Decommissioning Process”) and surrender the Original Premises to Landlord as quickly as
reasonably possible in the event Landlord has leased the Original Premises to a third-party tenant. In the event that Tenant fails to vacate the Original Premises and surrender and deliver exclusive possession of the Original Premises to Landlord on
or before the Surrender Date in accordance with the provisions of the Lease, then (subject to the terms of this Section 2.3, below and Section 15.4 of the Lease) Tenant shall be deemed to be in
holdover of the Original Premises from and after such date and shall be subject to the terms of 

  

					
		  	-2-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
Article 16 of the Lease. Subject to the terms of this Section 2.3, Tenant shall not be required to restore any improvements or alterations that are in the
Original Premises as of the date hereof, and may surrender the Original Premises in satisfaction of its surrender obligations under the Lease vacant, broom clean and otherwise in substantially the same condition as of the date hereof.
Notwithstanding the foregoing, if the Decommissioning Process has not been completed by the Surrender Date, then, subject to the terms of Section 5.3.4.4 of the Lease, during the period from the Surrender Date to the date
Tenant completes the Decommissioning Process (which may not exceed an additional thirty (30) days), Tenant shall not be considered to be in holdover but shall be required to pay Base Rent and Tenant’s Share of Direct Expenses for the
Original Premises at the rate applicable immediately prior to the Substitute Premises Commencement Date (prorated as applicable). 
 2.4
Representations of Tenant. Tenant represents and warrants to Landlord that (i) Tenant has not heretofore assigned or sublet all or any portion of its interest in the Lease or in the Original Premises; (ii) no other person,
firm or entity has any right, title or interest in the Lease or in the Original Premises through Tenant; (iii) Tenant has the full right, legal power and actual authority to enter into this First Amendment and to terminate Tenant’s lease
with respect to the Original Premises without the consent of any person, firm or entity; and (iv) Tenant has the full right, legal power and actual authority to bind Tenant to the terms and conditions hereof. Tenant further represents and
warrants to Landlord that as of the date hereof there are no, and as of the Surrender Date there shall not be any, mechanic’s liens or other liens encumbering all or any portion of the Original Premises, by virtue of any act or omission on the
part of Tenant, its predecessors, contractors, agents, employees, successors or assigns. Notwithstanding the termination of the Lease with respect to the Original Premises, the representations and warranties set forth in this
Section 2.4 shall survive the Surrender Date and Tenant shall be liable to Landlord for any inaccuracy or any breach thereof. 

2.5 Additional TI Allowance Payments. Pursuant to Section 4(b) of the Tenant Work Letter attached to the Lease, Tenant was
entitled to an Additional TI Allowance in the amount of $1,679,625.00. Tenant elected to utilize the entirety of the Additional TI Allowance, and accordingly Tenant was required to make Additional TI Allowance Payments in the amount of $22,159.18
throughout the Lease Term of the Original Premises, and therefore, notwithstanding the termination of the lease with respect to the Original Premises as of the Substitute Premises Commencement Date, Tenant shall nonetheless continue to be obligated
to make such payments through and including December 2027, and such obligation shall be deemed a Survival Obligation. 
 3.
Modification of Premises. 
 3.1 In General. Effective as of the date (the “Substitute Premises
Commencement Date”) the Premises are “Ready for Occupancy”, as defined in the Tenant Work Letter attached hereto as Exhibit B, Tenant shall lease from Landlord and Landlord shall
lease to Tenant the Substitute Premises on the terms and conditions set forth in the Lease, as hereby amended. To the extent a portion of the Substitute Premises is Ready for Occupancy prior to the Substitute Premises Commencement Date, provided
such occupancy will not delay Landlord’s completion of the Tenant Improvements and Landlord’s Work in the remainder of the Substitute Premises, Tenant shall have the right, by delivering written notice to Landlord, to occupy for the
conduct of its business any such portion. Such occupancy shall not accelerate the Substitute 

  

					
		  	-3-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
Premises Commencement Date or the Surrender Date and shall be on all of the terms of the Lease and this First Amendment, except that Tenant shall only pay Base Rent on the square footage occupied
by Tenant at the Monthly Base Rent Rate per rentable square foot set forth in Section 4.2 with respect to months 1-12 of the Substitute Premises Term and Tenant’s Share shall be
based on the square footage actually occupied by Tenant during such period. 
 3.2 Substitute Premises Term; Option Term.
Landlord and Tenant acknowledge that the Lease Term is scheduled to expire on December 14, 2027, pursuant to the terms of the Lease. Notwithstanding anything to the contrary set forth in the Lease, the Lease Term is hereby extended and shall
expire on the day prior to the tenth (10th) anniversary of the Substitute Premises Commencement Date, unless sooner terminated as provided in the Lease, as hereby amended (the “New
Lease Expiration Date”). The period of time beginning on the Substitute Premises Commencement Date and ending on the New Lease Expiration Date shall be referred to herein as the “Substitute Premises Term.” For purposes of
this Lease, the term “Substitute Year” shall mean each consecutive twelve (12) month period during the Substitute Premises Term. Landlord and Tenant acknowledge and agree that Tenant shall continue to have one (1) option
to extend the Lease Term for a period of ten (10) years in accordance with, and pursuant to the terms of, Section 2.2 of the Lease; provided, however, all references therein to the “Lease Term” shall be
deemed to refer to the “Substitute Premises Term”. 
 3.3 Condition of Substitute Premises. Except as
specifically set forth in the Lease or this First Amendment, including the Tenant Work Letter attached hereto as Exhibit B, Landlord shall not be obligated to provide or pay for any improvement work or
services related to the improvement of the Substitute Premises, and Tenant shall accept the Substitute Premises in its presently existing, “as-is” condition. Tenant also acknowledges that neither
Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Substitute Premises, the Building, or the Project or with respect to the suitability of the same for the conduct of Tenant’s business,
except as may be specifically set forth in the Lease, this First Amendment and the Tenant Work Letter attached hereto. Notwithstanding the foregoing, Landlord shall construct the improvements in the Substitute Premises pursuant to the terms of the
Tenant Work Letter attached hereto as Exhibit B (the “Tenant Work Letter”). Landlord shall deliver the Substitute Premises to Tenant in good, vacant, broom clean condition in compliance
with all applicable laws (to the extent required to allow the legal occupancy of the Substitute Premises), Ready for Occupancy, with all closures in connection with previous Hazardous Materials use completed and otherwise in the same condition as of
the date hereof, with the roof water-tight and shall cause the plumbing, electrical systems, fire sprinkler system, lighting and other building systems serving the Premises to be in good operating condition and repair on the Substitute Premises
Commencement Date. Notwithstanding anything in this Lease to the contrary, in connection with the foregoing Landlord shall, at Landlord’s sole cost and expense (which shall not be deemed an Operating Expense), repair or replace any failed or
inoperable portion of the Building mechanical systems serving the Premises during the first twelve (12) months of the Substitute Premises Term (“Warranty Period”), provided that the need to repair or replace was not caused by
the misuse, misconduct, damage, destruction, omissions, and/or negligence of Tenant, its subtenants and/or assignees, if any, or any company which is acquired, sold or merged with Tenant (collectively, “Tenant Damage”), or by any
modifications, Alterations or improvements constructed by or on behalf of Tenant. Landlord shall coordinate such work with Tenant and shall utilize commercially reasonable efforts to perform the same in a manner designed

  

					
		  	-4-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
to minimize interference with Tenant’s use of the Premises. To the extent repairs which Landlord is required to make pursuant to this Section 3.3 are necessitated in part by Tenant
Damage, then Tenant shall reimburse Landlord for an equitable proportion of the cost of such repair. Notwithstanding the foregoing, the terms of the last sentence of Section 1.1.1 of the Lease shall apply with respect to
the Substitute Premises. In addition, notwithstanding anything to the contrary herein or in the Lease, Landlord shall use commercially reasonable efforts to utilize any warranties to repair the Building and Building Systems before seeking to pass
through any repair costs to Tenant that could be considered capital expenditures. 
 3.4 Late Delivery. The last two
(2) sentences of Section 2.1 of the Lease are hereby deleted and shall be of no applicability to the Substitute Premises. If Landlord has not delivered possession of the Substitute Premises in the condition required by
Section 4, above, (1) on or before July 1, 2020, then, as Tenant’s sole remedy for such delay, the date Tenant is otherwise obligated to commence payment of rent with respect to the Substitute Premises shall
be delayed by one day for each day that the delivery date is delayed beyond such date or (2) October 1, 2020, then Tenant shall also have the right to cause this First Amendment to be null and void, upon written notice to Landlord (the
“First Amendment Termination Notice”) in which event this First Amendment shall be deemed null and void and of no further force or effect, the Lease shall remain unmodified and in full force and effect with respect to the
Original Premises and accordingly, Tenant shall continue to lease the Original Premises from Landlord pursuant to the terms of the Lease (without the modifications set forth in this First Amendment), whereupon any monies previously paid by Tenant to
Landlord with respect to periods after such termination shall be reimbursed to Tenant. The foregoing dates shall be extended to the extent of any delays in delivery of possession caused by Tenant Delay, as provided in
Section 1(j) of the Tenant Work Letter, war, terrorism, acts of God, natural disaster, civil unrest, governmental strike or area-wide of industry-wide labor disputes, inability to obtain services, labor, or materials or
reasonable substitutes therefor, or delays due to utility companies that are not the result of any action or inaction of Landlord (provided that such delay shall not extend any such date by more than ninety (90) days). 

4. Base Rent. 

4.1 Original Premises. On and prior to the Substitute Premises Commencement Date, Tenant shall continue to pay Base Rent for the
Original Premises in accordance with the terms of the Lease and Tenant shall have no obligation to pay Base Rent or Additional Rent with respect to the Original Premises thereafter (subject to the terms of Section 2.1 above). 

  

					
		  	-5-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 4.2 Substitute Premises. Notwithstanding anything to the contrary set forth in
the Lease, commencing on the Substitute Premises Commencement Date and continuing throughout the Substitute Premises Term, the Base Rent schedule set forth in Section 4 of the Summary of Basic Lease Information shall be
deleted and Tenant shall pay to Landlord monthly installments of Base Rent for the Substitute Premises as follows, and otherwise in accordance with the terms of the Lease: 
  

													
	 Substitute Year
	  	Annual Base Rent	 	  	Monthly Installment
of Base Rent	 	  	Approximate Monthly
Rental Rate per
Rentable Square Foot	 
	 1 (months 1 – 5)
	  	$	5,269,215.00	 	  	$	439,101.25	 	  	$	5.35	 
	 1 (months 6 – 12)
	  	$	10,538,430.00	 	  	$	878,202.50	 	  	$	5.35	 
	 2
	  	$	10,912,692.00	 	  	$	909,391.00	 	  	$	5.54	 
	 3
	  	$	11,294,636.22	 	  	$	941,219.69	 	  	$	5.73	 
	 4
	  	$	11,689,948.49	 	  	$	974,162.37	 	  	$	5.93	 
	 5
	  	$	12,099,096.68	 	  	$	1,008,258.06	 	  	$	6.14	 
	 6
	  	$	12,522,565.07	 	  	$	1,043,547.09	 	  	$	6.36	 
	 7
	  	$	12,960,854.85	 	  	$	1,080,071.24	 	  	$	6.58	 
	 8
	  	$	13,414,484.77	 	  	$	1,117,873.73	 	  	$	6.81	 
	 9
	  	$	13,883,991.73	 	  	$	1,156,999.31	 	  	$	7.05	 
	 10
	  	$	14,369,931.44	 	  	$	1,197,494.29	 	  	$	7.30	 

  

	*	 Note that for the first five (5) months of the Substitute Premises Term, Tenant’s Base Rent
obligation has been calculated as if the Substitute Premises contained only 82,075 rentable square feet. Such calculation shall not affect Tenant’s right to use the entire Substitute Premises, or Tenant’s obligations under this Lease with
respect to the entire Substitute Premises, including without limitation, Tenant’s obligation to pay Tenant’s Share of Direct Expenses with respect to the Substitute Premises, all in accordance with the terms and conditions of the Lease.

 5. Tenant’s Share of Direct Expenses. 

5.1 Original Premises. Notwithstanding anything in the Lease, as hereby amended, to the contrary (i) Tenant shall continue
to be obligated to pay Tenant’s Share of Direct Expenses in connection with the Original Premises which arise or accrue on and prior to the Substitute Premises Commencement Date in accordance with the terms of the Lease, and (ii) subject
to the terms of Section 2.3, above, Tenant shall not be obligated to pay Tenant’s Share of Direct Expenses in connection with the Original Premises attributable to any period of time on after the Substitute Premises
Commencement Date. 
 5.2 Substitute Premises. Commencing on the Substitute Premises Commencement Date, Tenant shall pay
Tenant’s Share of Direct Expenses which arise or accrue on and after the Substitute Premises Commencement Date in connection with the Substitute Premises in accordance with the terms of the Lease. Notwithstanding anything to the contrary set
forth in the Lease, as hereby amended, effective as of the Substitute Premises Commencement Date, for purposes of calculating Tenant’s Share of Direct Expenses in connection with the Premises, Tenant’s Share shall equal 100% of the
Substitute Building. 

  

					
		  	-6-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 6. Parking. Section 9 of the Summary is hereby
deleted and replaced with the following: “389 unreserved parking spaces, subject to the terms of Article 28 of the Lease.” All of the parking spaces available located within the podium under the Substitute
Building shall be reserved parking spaces for Tenant’s use, which shall be included in the total parking space count of 389 spaces. 

7. Services and Utilities. Effective as of the Substitute Premises Commencement Date, Sections 6.1 and 6.2 of the Lease
are deleted in their entirety and replaced with the following: 
 “6.1 In General. Landlord will be responsible, at
Tenant’s sole cost and expense (subject to the terms of Section 4.2.4, above), for the furnishing of heating, ventilation and air-conditioning, electricity, and water services to
the Premises. Landlord shall not provide janitorial or telephone services for the Premises. Tenant shall be solely responsible for performing all janitorial services and other cleaning of the Premises, all in compliance with applicable laws. The
janitorial and cleaning of the Premises shall be adequate to maintain the Premises in a manner consistent with First Class Life Sciences Projects. 

Tenant shall cooperate fully with Landlord at all times and abide by all reasonable regulations and requirements that Landlord may reasonably
prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems. Provided that Landlord agrees to provide and maintain and keep in continuous service utility connections to the Project, including
electricity, water and sewage connections, Landlord shall have no obligation to provide any services or utilities to the Building, including, but not limited to heating, ventilation and air-conditioning,
electricity, water, telephone, janitorial and interior Building security services, except as set forth in this Section 6.1, above. 

6.2 Tenant Payment of Utilities Costs. After the Lease Commencement Date, to the extent that any utilities (including without
limitation, electricity, gas, sewer and water) to the Building are separately metered or sub-metered to the Premises, such utilities shall either be contracted for and paid directly by Tenant to the applicable
utility provider, or reimbursed by Tenant to Landlord within thirty (30) days after billing. After the Lease Commencement Date, to the extent that any utilities (including without limitation, electricity, gas, sewer and water) to the Building
are not separately metered to the Premises, then Tenant shall pay to Landlord, within thirty (30) days after billing, an equitable portion of the Building utility costs, based on Tenant’s proportionate use thereof.” 

8. Repairs; Tenant Right to Perform Maintenance. The repair and maintenance obligations with respect to the Substitute Premises
shall remain as set forth in the Lease, provided that Tenant shall have the right, by delivering not less than six (6) months prior written notice (the “Tenant Maintenance Notice”) to Landlord, to assume the responsibility for
the routine maintenance of any of the Building Systems. If Tenant makes such election and delivers the Tenant Maintenance Notice to Landlord, then promptly following the date of delivery of the Tenant Maintenance Notice Landlord and Tenant will
enter into a lease amendment in the form of 

  

					
		  	-7-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
Exhibit C attached hereto (with necessary information provided necessary to complete the same), to replace Section 6.5 and Article 7 of the
Lease, and provide for Tenant’s maintenance of the Building Systems. 
 9. Alterations. After the Substitute Premises
Commencement Date, references in Section 8.1 of the Lease to “$10,000” and “$50,000” shall be changed to “$20,000”, “$100,000”, respectively. 

10. Letter of Credit. 

10.1 Increase in L-C Amount. The
“L-C”, as that term is defined in Section 21.1 of the Lease, currently held by Landlord is in the amount of $905,930.90. In connection with this First Amendment, Landlord and Tenant herby agree
that the L-C Amount shall be increased to a new total amount equal to $2,394,988.48 (the “New L-C Amount”). Accordingly, within ten (10) business
days after the full execution and delivery of this First Amendment, Tenant shall provide Landlord with either (i) a new L-C in such amended L-C Amount, which new L-C complies with the requirements of Article 21 of the Lease and Landlord shall concurrently return the existing L-C, or (ii) an amendment to the L-C (in form and content reasonably acceptable to Landlord) in order that the L-C, as amended, is in the New L-C Amount.
Section 21.7 of the Lease is hereby deleted. 
 10.2 Conditional Reduction in New L-C Amount. Notwithstanding anything to the contrary in this Lease, provided that (a) Tenant maintains a market capitalization in excess of Two Billion Dollars ($2,000,000,000.00) (the “Market
Cap Test”) as measured as the product of the number of shares outstanding and the closing price of the stock on the last business day of each month during the third (3rd) Substitute Year,
and (b) Tenant is not in default beyond applicable notice and cure periods under this Lease at the expiration of the third (3rd) Substitute Year, the New
L-C Amount shall be reduced by fifty percent (50%) upon the first day of the fourth (4th) Substitute Year. If Tenant does not meet the Market Cap Test in
the third (3rd) Substitute Year, then on the first time after the third (3rd) Substitute Year that Tenant meets the Market Cap Test for a
continuous twelve (12) month period, and is not in default beyond applicable notice and cure periods under this Lease, then the New L-C Amount shall be reduced by fifty percent (50%). 

11. Exterior Signage. In connection with the Substitute Premises, Tenant shall be entitled to the Tenant Signage set forth in
Section 23.1 of the Lease with respect to the Substitute Premises, and in addition, Tenant Signage shall include one (1) sign on the building monument sign located outside the Substitute Building entry and sign(s) on the south and east
side(s) of the top of the Substitute Building in the locations reasonably and mutually agreed upon by Landlord and Tenant (but no more than one (1) sign per side of the Substitute Building), subject to the receipt of all governmental approvals
and Landlord’s approval. 
 12. Broker. Landlord and Tenant hereby warrant to each other that they have had no dealings
with any real estate broker or agent in connection with the negotiation of this First Amendment other than Jones Lang LaSalle and CBRE, Inc. (collectively, the “Broker”), and that they know of no other real estate broker or agent
who is entitled to a commission in connection with this First Amendment. Each party agrees to indemnify and defend the other party against and hold the other party harmless from and against any and all claims, demands, losses, liabilities,

  

					
		  	-8-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys’ fees) with respect to any leasing commission or equivalent compensation alleged to be owing
on account of the indemnifying party’s dealings with any real estate broker or agent, other than the Broker accruing by, through or under the indemnifying party. The terms of this Section 12 shall survive the
expiration or earlier termination of the Lease, as hereby amended. 
 13. California Required Disclosures. For purposes of
Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges that the Common Areas, the Original Premises, and the Substitute Premises have not undergone inspection by a Certified Access
Specialist (CASp). As required by Section 1938(e) of the California Civil Code, Landlord hereby states as follows: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply
with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant
from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp
inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.” In furtherance of the foregoing, Landlord and
Tenant hereby agree as follows: (a) any CASp inspection requested by Tenant shall be conducted, at Tenant’s sole cost and expense, by a CASp approved in advance by Landlord; and (b) pursuant to Article 24 of the Lease, but
subject to Section 10.2 of the Lease, Tenant, at its cost, is responsible for making any repairs within the Premises to correct violations of construction-related accessibility standards; and, if anything done by or for
Tenant in its use or occupancy of the Premises shall require repairs to the Building (outside the Premises) to correct violations of construction-related accessibility standards, then Tenant shall, at Landlord’s option, either perform such
repairs at Tenant’s sole cost and expense or reimburse Landlord upon demand, as Additional Rent, for the cost to Landlord of performing such repairs. The terms of this Section 13 do not amend or reduce the obligations of Landlord and
Tenant set forth in the Lease regarding compliance with applicable laws and repair and maintenance of the Premises and the Project, but apply solely to the obligations of Landlord and Tenant in connection with Tenant’s election to conduct a
CASp inspection hereunder 
 14. Generator; Chemical Storage Room. The Substitute Building will have (a) a
“Generator” as provided in Section 6.5 of the Lease (the terms of which are subject to modification in the event Tenant delivers the Tenant Maintenance Notice), and (b) a “Chemical Storage Room” as
provided in Section 6.6 of the Lease, and the terms of such Section 6.6 shall apply with respect to the Substitute Premises. 

15. No Deed of Trust. Landlord hereby represents and warrants to Tenant that the Project is not currently subject to any ground
lease, or to the lien of any mortgage or deed of trust. 
 16. Notice Address. After the Substitute Premises Commencement
Date, notice to Tenant shall be sent to the Substitute Premises, Attn: Chief Legal Officer. 

  

					
		  	-9-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 17. Construction Period. The provisions of Sections 10.7 and
10.8 of the Lease shall apply to the Substitute Premises and Landlord’s construction of Landlord’s Work as described in Exhibit B, with the “Construction Period” to mean the period from the date of full
execution and delivery of this First Amendment to the date Landlord completes construction of Landlord’s Work (including any Additional Base Building Items), and Common Areas, regardless of any Tenant Delay and without regard to the effect of
any provisions of the Lease, as amended by this First Amendment, pursuant to which the Substitute Premises are deemed Ready for Occupancy in advance of its actual occurrence. 

18. Tenant’s Property. Tenant’s Property, as defined in Section 8.5 of the Lease, shall also
include any (a) audio-visual equipment, including monitors, (b) NMR and (c) sound masking electronic devices, in each case installed by Tenant at Tenant’s expense. 

19. Direct Expenses. Upon Tenant’s request, Landlord shall use commercially reasonable efforts to promptly provide Tenant
with any additional information reasonably requested by Tenant to support Direct Expenses Tenant is requested to pay under the Lease. 
 20.
Transfer Premiums. Section 14.3 of the Lease is hereby revised to insert at the end of subpart (i) the following: “(which may include the unamortized cost of the Tenant Improvements to the extent
paid for by Tenant directly rather than through the Additional TI Allowance)”. In addition, the rent reduction under Section 4.2 of this First Amendment in the first five (5) months following the Substitute
Premises Commencement Date shall not be taken into consideration when calculating the Transfer Premium. 
 21. Cell Reception
Issue. The parties acknowledge that there is currently a problem in the Project with cell phone reception inside the buildings. Prior to the Substitute Premises Commencement Date, Landlord shall, at Landlord’s sole cost (and
not as an Operating Expense), use commercially reasonable efforts to remedy this problem so that there is reasonable cell reception from all of the major carriers within the Original Building and Substitute Building. 

22. Conflict; No Further Modification. In the event of any conflict between the terms and provisions of the Lease and the terms
and provisions of this First Amendment, the terms and provisions of this First Amendment shall prevail. Except as set forth in this First Amendment, all of the terms and provisions of the Lease shall apply with respect to the Substitute Premises and
shall remain unmodified and in full force and effect. 
 [signatures follow on next page] 

  

					
		  	-10-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 IN WITNESS WHEREOF, this First Amendment has been executed as of the day and year first
above written. 
  

													
	LANDLORD:	 	TENANT:
			
	 HCP OYSTER POINT III LLC,
 a
Delaware limited liability company
	 		 	 GLOBAL BLOOD THERAPEUTICS, INC.,
 a
Delaware corporation

					
	By:	 	 /s/ Scott Bohn
	 		 	By:	 	 /s/ Ted W. Love

		 	Name:	 	 Scott Bohn
	 		 		 	Name:	 	 Ted W. Love

		 	Its:	 	 Vice President
	 		 		 	Its:	 	 CEO

						
		 		 		 		 	By:	 	 /s/ Jeffrey Farrow

		 		 		 		 		 	Name:	 	 Jeffrey Farrow

		 		 		 		 		 	Its:	 	 CFO

  

  

					
		  	-11-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 EXHIBIT A 

OUTLINE OF SUBSTITUTE PREMISES 
  

 

  

					
		  	 EXHIBIT A

-1-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 

 

  

					
		  	-2-	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 EXHIBIT B 

TENANT WORK LETTER 

1. Defined Terms. As used in this Tenant Work Letter, the following capitalized terms have the following meanings: 

(a) Approved TI Plans: Plans and specifications prepared by the applicable Architect for the Tenant Improvements and approved by
Landlord and Tenant in accordance with Paragraph 2 of this Tenant Work Letter, subject to further modification from time to time to the extent provided in and in accordance with such Paragraph 2. 

(b) Architect: Landlord shall engage DGA with respect to any Tenant Improvements which Landlord is to cause to be constructed
pursuant to this Tenant Work Letter. 
 (c) Tenant Change Request: See definition in Paragraph 2(d)(ii) hereof. 

(d) Final TI Working Drawings: See definition in Paragraph 2(a) hereof. 

(e) General Contractor: Landmark Builders, Hathaway Dinwiddie or another general contractor reasonably selected by Landlord and
in any case approved by Tenant as a result of competitive bidding of the cost of the Tenant Improvements with respect to Landlord’s TI Work. Tenant shall have no right to direct or control such General Contractor. 

(f) Landlord’s TI Work: Any Tenant Improvements which Landlord is to construct or install pursuant to this Tenant Work
Letter or by mutual agreement of Landlord and Tenant from time to time. 
 (g) Project Manager. Project Management Advisors,
Inc., or any other project manager designated by Landlord in its reasonable discretion from time to time to act in a supervisory, oversight, project management or other similar capacity on behalf of Landlord in connection with the design and/or
construction of the Tenant Improvements. 
 (h) Punch List Work: Minor corrections of construction or decoration details, and
minor mechanical adjustments, that are required in order to cause any applicable portion of the Tenant Improvements or Landlord’s Work as constructed to conform to the Approved TI Plans or this Tenant Work Letter in all material respects and
that do not materially interfere with Tenant’s use or occupancy of the Substitute Building and the Substitute Premises. 
 (i)
Substantial Completion Certificate: See definition in Paragraph 3(a) hereof. 

  

					
		  	 EXHIBIT B

-3-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 (j) Tenant Delay: Any of the following types of delay in the completion of
construction of Landlord’s TI Work (but in each instance, only to the extent that any of the following has actually and proximately caused substantial completion of Landlord’s TI Work to be delayed): 

(i) Any delay resulting from Tenant’s failure to furnish, in a timely manner, information reasonably requested by Landlord
or by Landlord’s Project Manager in connection with the design or construction of Landlord’s TI Work, or from Tenant’s failure to approve in a timely manner any matters requiring approval by Tenant; 

(ii) Any delay resulting from Tenant Change Requests initiated by Tenant, including any delay resulting from the need to revise
any drawings or obtain further governmental approvals as a result of any such Tenant Change Request; or 
 (iii) Any delay
caused by Tenant (or Tenant’s contractors, agents or employees) materially interfering with the performance of Landlord’s TI Work, provided that Landlord shall have given Tenant prompt notice of such material interference and, before the
first time a Tenant Delay is deemed to have occurred as a result of such delay, such interference has continued for more than twenty-four (24) hours after Tenant’s receipt of such notice. 

(k) Tenant Improvements: The improvements to or within the Substitute Building shown on the Approved TI Plans from time to time
and to be constructed by Landlord pursuant to the Lease (as amended) and this Tenant Work Letter. The term “Tenant Improvements” does not include the improvements existing in the Substitute Building and Substitute Premises at the date of
execution of the First Amendment. Landlord hereby acknowledges that the Tenant Improvements constructed in the Substitute Premises pursuant to the terms of this Tenant Work Letter shall not be subject to removal. 

(l) Unavoidable Delays: Delays due to acts of God, acts of public agencies, labor disputes, strikes, fires, freight embargoes,
inability (despite the exercise of due diligence) to obtain supplies, materials, fuels or permits, or other causes or contingencies (excluding financial inability) beyond the reasonable control of Landlord or Tenant, as applicable. Landlord shall
use commercially reasonable efforts to provide Tenant with prompt notice of any Unavoidable Delays. 
 (m) Capitalized terms not otherwise
defined in this Tenant Work Letter shall have the definitions set forth in the Lease (as amended); provided, however, all references to Premises and Building shall mean the Substitute Premises and the Substitute Building, respectively, and all
references to the Lease shall mean the Lease, as modified by the First Amendment. 
 2. Plans and Construction. Landlord and
Tenant shall comply with the procedures set forth in this Paragraph 2 in preparing, delivering and approving matters relating to the Tenant Improvements. 

(a) Approved Plans and Working Drawings for Tenant Improvements. Tenant shall promptly and diligently work with the Architect to cause
to be prepared and delivered to Landlord for approval (which approval shall not be unreasonably withheld, conditioned or delayed by Landlord) proposed schematic plans and outline specifications for the Tenant Improvements. Following mutual approval
of such proposed schematic plans and outline specifications by Landlord and by Tenant (as so approved, the “Approved Schematic Plans”), Tenant shall then work with the Architect to cause to be prepared, promptly and diligently
(assuming timely delivery 

  

					
		  	 EXHIBIT B

-4-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
by Landlord of any information and decisions required to be furnished or made by Landlord in order to permit preparation of final working drawings, all of which information and decisions Landlord
will deliver promptly and with reasonable diligence), and delivered to Landlord for approval (which approval shall not be unreasonably withheld, conditioned or delayed by Landlord) final detailed working drawings and specifications for the Tenant
Improvements, including (without limitation) any applicable life safety, mechanical, electrical and plumbing working drawings and final architectural drawings (collectively, “Final TI Working Drawings”), which Final TI Working
Drawings shall substantially conform to the Approved Schematic Plans. Upon receipt from Tenant of proposed schematic plans and outline specifications, proposed Final TI Working Drawings, any other plans and specifications, or any revisions or
resubmittals of any of the foregoing, as applicable, Landlord shall promptly and diligently (and in all events within 10 business days after receipt in the case of an initial submittal of schematic plans and outline specifications or proposed Final
TI Working Drawings, and within 7 business days after receipt in the case of any other plans and specifications or any revisions or resubmittals of any of the foregoing) either approve such proposed schematic plans and outline specifications or
proposed Final TI Working Drawings, as applicable, or set forth in writing with particularity any changes necessary to bring the aspects of such proposed schematic plans and outline specifications or proposed Final TI Working Drawings into a form
which will be reasonably acceptable to Landlord. Upon approval of the Final TI Working Drawings by Landlord and Tenant, the Final TI Working Drawings shall constitute the “Approved TI Plans,” superseding (to the extent of any
inconsistencies) any inconsistent features of the previously existing Approved Schematic Plans. Tenant shall respond to any request for information or approval of plans or drawings from Landlord or Architect within seven (7) business days.
Tenant acknowledges that the Tenant Improvements will include the items set forth on Schedule 2 to this Exhibit B, in order to allow the Substitute Premises to achieve a LEED “Silver” certification level. 

(b) Cost of Improvements. “Cost of Improvement” shall mean, with respect to any item or component for which a cost
must be determined in order to allocate such cost, or an increase in such cost, to Tenant pursuant to this Tenant Work Letter, the sum of the following (unless otherwise agreed in writing by Landlord and Tenant with respect to any specific item or
component or any category of items or components): (i) all sums paid to contractors or subcontractors for labor and materials furnished in connection with construction of such item or component; (ii) all costs, expenses, payments, fees and
charges (other than penalties) paid to or at the direction of any city, county or other governmental or quasi-governmental authority or agency which are required to be paid in order to obtain all necessary governmental permits, licenses, inspections
and approvals relating to construction of such item or component; (iii) engineering and architectural fees for services rendered in connection with the design and construction of such item or component (including, but not limited to, the
Architect for such item or component and an electrical engineer, mechanical engineer, structural engineer and civil engineer, if applicable); (iv) sales and use taxes; (v) testing and inspection costs; (vi) the cost of power, water
and other utility facilities and the cost of collection and removal of debris required in connection with construction of such item or component; (vii) costs for builder’s risk insurance; and (viii) all other “hard” and
“soft” costs incurred in the construction of such item or component in accordance with the Approved TI Plans (if applicable) and this Tenant Work Letter; provided that the Cost of Improvements shall not include any internal or
third-party costs incurred by Landlord except as provided in Section 2(e). 

  

					
		  	 EXHIBIT B

-5-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 (c) Construction of Landlord’s TI Work. Following completion of the
Approved TI Plans, Landlord shall apply for and use reasonable efforts to obtain the necessary permits and approvals to allow construction of all Tenant Improvements. Upon receipt of such permits and approvals, Landlord shall, at Tenant’s
expense (subject to Landlord’s payment of the Tenant Improvement Allowance and to the extent requested by Tenant, the Additional TI Allowance), construct and complete the Tenant Improvements substantially in accordance with the Approved TI
Plans, subject to Unavoidable Delays and Tenant Delays (if any). Such construction of the Tenant Improvements and Landlord’s Work shall be performed in a neat, good and workmanlike manner, free of defects, using new materials and equipment of
good quality, and shall materially conform to all applicable laws, rules, regulations, codes, ordinances, requirements, covenants, conditions and restrictions applicable thereto in force at the time such work is completed. Landlord shall cause
Hathaway Dinwiddie, Landmark Builders and any other potential general contractors requested by Tenant and reasonably approved by Landlord to bid on general conditions and fee for construction of the Tenant Improvements on an open book basis and
provide an estimate for the direct cost of the Tenant Improvements. All bids will be opened together with Landlord selecting the general contractor to construct the Tenant Improvements, subject to the reasonable approval of Tenant. Tenant shall also
have the right to review all subcontractor competitive pricing budgets and approve all subcontractors engaged by the General Contractor, which approval shall not be unreasonably withheld, conditioned or delayed. Landlord shall enter into a
stipulated sum or guaranteed maximum price construction contract with the General Contractor in the amount of the construction costs approved by Landlord and Tenant. 

(d) Changes. 

(i) If Landlord determines at any time that changes in the Final TI Working Drawings or in any other aspect of the Approved TI
Plans relating to any item of Landlord’s TI Work are required as a result of applicable law or governmental requirements, or are required at the insistence of any other third party whose approval may be required with respect to the Tenant
Improvements, or are required as a result of unanticipated conditions encountered in the course of construction, then Landlord shall promptly (A) advise Tenant of such circumstances and (B) at Tenant’s sole cost and expense, subject
to Landlord’s payment of the Tenant Improvement Allowance and to the extent requested by Tenant, the Additional TI Allowance, cause revised Final TI Working Drawings to be prepared by the Architect and submitted to Tenant, for Tenant’s
approval, which shall not be unreasonably withheld. Failure of Tenant to deliver to Landlord written notice of disapproval and specification of such required changes on or before any deadline reasonably specified by Landlord (which shall not be less
than three (3) business days after delivery thereof to Tenant) shall constitute and be deemed to be a Tenant Delay to the extent Landlord is delayed in completing Landlord’s TI Work. 

(ii) If Tenant at any time desires any changes, alterations or additions to the Final TI Working Drawings, Tenant shall submit
a detailed written request to Landlord specifying such changes, alterations or additions (a “Tenant Change Request”). Upon receipt of any such request, Landlord shall promptly notify Tenant of (A) whether the matters proposed
in the Tenant Change Request are approved by Landlord (which approval shall not be unreasonably withheld, conditioned or delayed by Landlord), (B) Landlord’s estimate of the number of days of delay, if any, which shall be caused in the
construction 

  

					
		  	 EXHIBIT B

-6-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
of the Tenant Improvements by such Tenant Change Request if implemented (including, without limitation, delays due to the need to obtain any revised plans or drawings and any governmental
approvals), and (C) Landlord’s estimate of the increase, if any, which shall occur in the cost of design, permitting, project management and construction of the Tenant Improvements affected by such Tenant Change Request if such Tenant
Change Request is implemented (including, but not limited to, any costs of compliance with laws or governmental regulations that become applicable because of the implementation of the Tenant Change Request). If Landlord approves the Tenant Change
Request and Tenant notifies Landlord in writing, within three (3) business days after receipt of such notice from Landlord, of Tenant’s approval of the Tenant Change Request (including the estimated delays and cost increases, if any,
described in Landlord’s notice), then Landlord shall cause such Tenant Change Request to be implemented and Tenant shall be responsible for all actual costs or cost increases resulting from or attributable to the implementation of the Tenant
Change Request, and any delays resulting therefrom shall be deemed to be a Tenant Delay (subject to Landlord’s payment of the Tenant Improvement Allowance, and to the extent requested by Tenant, the Additional TI Allowance). If Tenant fails to
notify Landlord in writing of Tenant’s approval of such Tenant Change Request within said three (3) business day period, then such Tenant Change Request shall be deemed to be withdrawn and shall be of no further effect. 

(e) Project Management. Unless and until revoked by Landlord by written notice delivered to Tenant, Landlord hereby
(i) delegates to Project Manager the authority to exercise all approval rights, supervisory rights and other rights or powers of Landlord under this Tenant Work Letter with respect to the design and construction of the Tenant Improvements, and
(ii) requests that Tenant work with Project Manager with respect to any logistical or other coordination matters arising in the course of construction of the Tenant Improvements, including monitoring Tenant’s compliance with its
obligations under this Tenant Work Letter and under the Lease (as amended) with respect to the design and construction of the Tenant Improvements. Tenant acknowledges the foregoing delegation and request, and agrees to cooperate reasonably with
Project Manager as Landlord’s representative pursuant to such delegation and request. Fees and charges of Project Manager for such services shall be at Tenant’s sole expense, subject to Landlord’s payment of the Tenant Improvement
Allowance. Such fees shall equal the sum of (X) the product of (A) 2.65% and (B) the amount of the Tenant Improvement Allowance and Additional TI Allowance which Tenant elects to utilize, and (Y) the product of (C) 2.0% and
(D) the amount of Tenant Funds Amount which Tenant elects to utilize. 
 3. Completion. 

(a) When Landlord receives written certification from Architect that construction of the Tenant Improvements and Landlord’s Work has been
completed in accordance with the Approved TI Plans and Section 3(e) below (except for Punch List Work), Landlord shall prepare and deliver to Tenant a certificate (or separate certificates for the Tenant Improvements and
Landlord’s Work) signed by Landlord, Architect and General Contractor (the “Substantial Completion Certificate”) (i) certifying that the construction of the Tenant Improvements and Landlord’s Work has been substantially
completed in a good and workmanlike manner in accordance with the Approved TI Plans and Section 3(e) below in all material respects, subject only to completion of Punch List Work, and specifying the date of that completion,
and (ii) 

  

					
		  	 EXHIBIT B

-7-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
certifying that the Tenant Improvements and Landlord’s Work comply in all material respects with all laws, rules, regulations, codes, ordinances, requirements, covenants, conditions and
restrictions applicable thereto at the time of such delivery. Upon receipt by Tenant of the Substantial Completion Certificate and tender of possession of all of the Substitute Premises by Landlord to Tenant, and receipt of any certificate of
occupancy or its legal equivalent, or other required sign-offs from any applicable governmental authority, allowing the legal occupancy of the Substitute Premises, the Tenant Improvements will be deemed delivered to Tenant and “Ready for
Occupancy” for all purposes of the First Amendment (subject to Landlord’s continuing obligations with respect to any Punch List Work, and to any other express obligations of Landlord under the First Amendment or this Tenant Work Letter
with respect to such Tenant Improvements). 
 (b) Immediately prior to delivery of the Substantial Completion Certificate for the Tenant
Improvements and Landlord’s Work, Project Manager or other representatives of Landlord shall conduct one or more “walkthroughs” of the Substitute Building with Tenant and Tenant’s representatives, to identify any items of Punch
List Work that may require correction and to prepare a joint punch list reflecting any such items, following which Landlord shall diligently complete the Punch List Work reflected in such joint punch list. The Punch List Work shall be attached to
the Substantial Completion Certificate, and shall not include damage caused by Tenant or any of Tenant’s agents in connection with any work performed by Tenant in the Substitute Premises, or required as a result of Tenant’s move-in to the Substitute Premises. At any time within thirty (30) days after delivery of such Substantial Completion Certificate, Tenant shall be entitled to submit one or more lists to Landlord supplementing
such joint punch list by specifying any additional items of Punch List Work to be performed on the applicable Tenant Improvements and Landlord’s Work, and upon receipt of such list(s), Landlord shall diligently complete such additional Punch
List Work. Promptly after Landlord provides Tenant with the Substantial Completion Certificate and completes all applicable Punch List Work for the Substitute Building, Landlord shall cause the recordation of a Notice of Completion (as defined in
the California Civil Code) with respect to the Tenant Improvements. 
 (c) All construction, product and equipment warranties and guaranties
obtained by Landlord with respect to the Tenant Improvements and Landlord’s Work shall, to the extent reasonably obtainable, include a provision that such warranties and guaranties shall also run to the benefit of Tenant, and Landlord shall
cooperate with Tenant in a commercially reasonable manner to assist in enforcing all such warranties and guaranties for the benefit of Tenant. 

(d) Notwithstanding any other provisions of this Tenant Work Letter or of the Lease (as amended), if Landlord is delayed in substantially
completing any of the Tenant Improvements as a result of any Tenant Delay, then notwithstanding any other provision of the First Amendment to the contrary, then the Substitute Premises shall be deemed to have been Ready for Occupancy on the date the
Substitute Premises would have been Ready for Occupancy absent such Tenant Delay. 
 (e) Notwithstanding any other provisions of this Tenant
Work Letter or of the First Amendment, Landlord shall be responsible, at Landlord’s sole cost and expense, and without deduction from the Tenant Improvement Allowance, to construct and deliver the Base Building and “Warm Shell”
components of the Substitute Premises (“Landlord’s Work”), which shall consist of the items set forth on Schedule 1 to this Exhibit B and the work described in the last sentence of
Section 6.2 of the Lease (the “Warm Shell Schedule”). 

  

					
		  	 EXHIBIT B

-8-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 (f) Construction of Additional Base Building Items. To the extent that the
Final TI Working Drawings contain any structural items, or items which would not reasonably be categorized as “normal tenant improvements” under applicable GAAP standards (the “Additional Base Building Items”), then such
Additional Base Building Items shall not be constructed as a part of the Landlord’s TI Work or the Tenant Improvements, but instead will be constructed by Landlord as a part of the Landlord’s Work. The cost of construction of the
Additional Base Building Items (the “Additional Base Building Costs”) shall be borne by Landlord. Before commencing construction thereof, Landlord shall obtain a reasonable, good faith bid for the Additional Base Building Items from
the General Contractor, which bid shall take into account all reasonable factors, including, without limitation, reasonable contingencies in connection therewith, Landlord shall notify Tenant of the amount of such bid (the “Estimated Base
Building Costs”), and the amount of the Tenant Improvement Allowance shall be reduced by the amount of the Estimated Base Building Costs. Landlord shall have the right to disapprove any aspect of the Final TI Working Drawing that would
result in Additional Base Building Costs in excess of the then remaining Tenant Improvement Allowance, so that, while the Tenant Improvement Allowance may be reduced, under no circumstances would Tenant be required to pay for any Additional Base
Building Items with its own funds. 
 4. Payment of Costs. 

(a) Tenant Improvement Allowance. Subject to any restrictions, conditions or limitations expressly set forth in this Tenant Work
Letter or in the First Amendment or as otherwise expressly provided by mutual written agreement of Landlord and Tenant, the cost of construction of the Tenant Improvements shall be paid or reimbursed by Landlord up to a maximum amount equal to
$23,801,750.00 (the “Tenant Improvement Allowance”), which amount is being made available by Landlord to be applied towards the Cost of Improvements for the construction of the Tenant Improvements in the Substitute Premises. Tenant
shall be responsible, at its sole cost and expense, for payment of the entire Cost of Improvements of the Tenant Improvements in excess of the Tenant Improvement Allowance (such excess amount is referred to herein as the “Tenant Funds
Amount”), including (but not limited to) any costs or cost increases incurred as a result of delays (unless caused by Landlord), governmental requirements or unanticipated conditions (unless caused by Landlord), and for payment of any and
all costs and expenses relating to any alterations, additions, improvements, furniture, furnishings, equipment, fixtures and personal property items which are not eligible for application of Tenant Improvement Allowance funds under the restrictions
expressly set forth below in this paragraph, but Tenant shall be entitled to use or apply the entire Tenant Improvement Allowance toward the Cost of Improvements of the Tenant Improvements (subject to any applicable restrictions, conditions,
limitations, reductions or charges set forth in the First Amendment or in this Tenant Work Letter) prior to being required to expend any of Tenant’s own funds for the Tenant Improvements. The funding of the Tenant Improvement Allowance shall be
made on a monthly basis or at other convenient intervals mutually approved by Landlord and Tenant and in all other respects shall be based on such commercially reasonable disbursement conditions and procedures as Landlord, Project Manager and
Landlord’s lender (if any) may reasonably prescribe. Notwithstanding the foregoing provisions, under no circumstances shall the Tenant Improvement Allowance or any 

  

					
		  	 EXHIBIT B

-9-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
portion thereof be used or useable by Tenant for any moving or relocation expenses of Tenant or cabling expenses. Notwithstanding anything to the contrary herein, the Tenant Improvements shall
not include (and Landlord shall be solely responsible for and the Tenant Improvement Allowance shall not be used for) the following: (a) costs incurred due to the presence of any Hazardous Materials in the Substitute Premises, if any, but with
respect to removal and remediation of any such Hazardous Materials, only to the extent such removal or remediation is required by Applicable Laws enforced as of the date of this First Amendment for improvements in the Substitute Premises generally
(as opposed to the specific Tenant Improvements) and to the extent the same required in order to allow Tenant to obtain a certificate of occupancy or its legal equivalent, for the Substitute Premises for the Permitted Use assuming a normal and
customary occupancy density; (b) costs to bring the Project into compliance with Applicable Laws to the extent required in order to allow Tenant to obtain a certificate of occupancy or its legal equivalent, for the Substitute Premises for the
Permitted Use assuming a normal and customary office occupancy density; (c) construction costs in excess of the contract amount stated in the contract with the General Contractor, as approved by Tenant (not to be unreasonably withheld), except
for increases set forth in change orders approved by Tenant; (d) wages, labor and overhead for overtime and premium time unless approved by Tenant (which approval shall not be unreasonably withheld, conditioned or delayed); (e) attorneys’
fees incurred in connection with negotiation of construction contracts, and attorneys’ fees, experts’ fees and other costs in connection with disputes with third parties; (f) interest and other costs of financing construction costs;
(g) costs incurred as a consequence construction defects or default by a contractor; (h) costs as a consequence of casualties; (i) penalties and late charges attributable to Landlord’s failure to pay construction costs; and
(j) costs due to compliance with the soil management plan for the Project or its appendices. 
 (b) Additional TI
Allowance. In addition to the Tenant Improvement Allowance, Tenant shall have the right, by written notice to Landlord given on or before the Substitute Premises Commencement Date, to use up to $25.00 per RSF of the Substitute Premises
(i.e., up to $4,103,750.00) (the “Additional TI Allowance”) towards the payment of the costs of the Tenant Improvement Allowance Items. In the event Tenant exercises its right to use all or any portion of the Additional TI
Allowance, Tenant shall be required to pay Landlord, commencing on the date the Tenant Improvements are completed (the “Additional Payment Commencement Date”), the “Additional TI Allowance Payment,” as that term is defined
below, in consideration of Landlord provision of the Additional TI Allowance. The “Additional TI Allowance Payment” shall be determined as the missing component of an annuity, which annuity shall have (i) the amount of the
Additional TI Allowance utilized by Tenant as the present value amount, (ii) a number equal to the number of full calendar months then remaining in the Substitute Premises Term as the number of payments, (iii) a monthly interest factor
equal to 0.8333%, which is equal to ten percent (10%) divided by twelve (12) months per year, and (iv) the Additional TI Allowance Payment as the missing component of the annuity, and shall not be subject to annual escalations. Following
the calculation of the Additional TI Allowance Payment, Landlord and Tenant will enter into a lease amendment in the form of Exhibit G attached to the Lease, to confirm the amount thereof. 

(c) Tenant Funds. For additional funds required to complete the cost of the work, that are in excess of, or elected by the
Tenant to be used in place of the Tenant Improvement Allowance, and the Additional TI Allowance, these shall be considered “Tenant Funds.” The total cost to construct the Tenant Improvements as managed by Landlord and the
Project Manager 

  

					
		  	 EXHIBIT B

-10-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
under this Work Letter shall be the “Project Budget.” The Landlord understands that at the time of the agreed upon Guaranteed Maximum Price (GMP), the Tenant Funds amount is an
estimate and exact costs will not be known until project closeout. The Tenant is required, at the time of agreement of the GMP, to provide a purchase order to the Landlord for the full estimated amount of the Tenant Funds, provided that Tenant
shall not be required to make payment, if any, until the close out of the project and a true up of costs are provided to Tenant. In the event the Tenant Funds at project closeout are less than the amount agreed upon within the Project Budget,
the Landlord will only bill the Tenant for the Tenant Funds that have been utilized. In the event the Tenant Funds exceed the amount agreed upon within the Project Budget, through added scope changes, the Tenant shall provide additional
purchases orders to the Landlord, which will be included in the Tenant Change Request process that the Landlord’s representative administers. 

5. No Agency. Nothing contained in this Tenant Work Letter shall make or constitute Tenant as the agent of Landlord. 

6. Tenant Access. Provided that Tenant and its agents do not interfere with Contactor’s work in the Substitute Building and
the Substitute Premises (provided all of Tenant’s agents retained directly by Tenant shall all be union labor in compliance with the then existing master labor agreements), Contractor and Landlord shall allow Tenant access to the Substitute
Premises prior to the Substantial Completion of the Landlord’s TI Work without payment of Rent for the purpose of Tenant installing equipment or fixtures (including Tenant’s data and telephone equipment) in the Substitute Premises and
preparing the Substitute Premises for occupancy (and at any time after First Amendment execution as Tenant may reasonably request for purposes of design and planning). Prior to Tenant’s entry into the Substitute Premises as permitted by the
terms of this Section 6, Tenant shall submit a schedule to Landlord and Contractor, for their approval, which schedule shall detail the timing and purpose of Tenant’s entry. Tenant shall hold Landlord harmless from and
indemnify, protect and defend Landlord against any loss or damage to the Substitute Building or Substitute Premises and against injury to any persons caused by Tenant’s actions pursuant to this Section 6. 

7. Miscellaneous. All references in this Tenant Work Letter to a number of days shall be construed to refer to calendar days,
unless otherwise specified herein. In all instances where Landlord’s or Tenant’s approval is required, if no written notice of disapproval is given within the applicable time period, at the end of that period Landlord or Tenant shall be
deemed to have given approval (unless the provision requiring Landlord’s or Tenant’s approval expressly states that non-response is deemed to be a disapproval or withdrawal of the pending action or
request, in which event such express statement shall be controlling over the general statement set forth in this sentence) and the next succeeding time period shall commence. If any item requiring approval is disapproved by Landlord or Tenant (as
applicable) in a timely manner, the procedure for preparation of that item and approval shall be repeated. Landlord hereby acknowledges that Tenant shall not be required to restore the initial Tenant Improvements constructed in the Substitute
Premises pursuant to the terms of this Tenant Work Letter upon the termination of the Lease. 

  

					
		  	 EXHIBIT B

-11-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 8. Time Deadlines. Tenant shall use commercially reasonable, good faith,
efforts and all due diligence to cooperate with the Architect, General Contractor and Landlord to complete all phases of the construction drawings set forth in this Tenant Work Letter and the permitting process and to receive the permits as soon as
possible after the execution of the. The applicable dates for approval of items, plans and drawings as described in this Tenant Work Letter are set forth and further elaborated upon in Schedule 3 to this Exhibit B attached hereto (the “Time
Deadlines”), attached hereto. Tenant agrees to utilize commercially reasonable efforts to comply with the Time Deadlines. 
 9.
Rooftop Space. Tenant hereby acknowledges that to the extent either (i) any portion of the Tenant Improvements, or (ii) any of Tenant’s equipment installed in the Substitute Premises, requires a portion of the roof to be
utilized by Tenant, that Tenant shall only be permitted to utilize that certain portion of the roof designated as on Schedule 4 to this Exhibit B (the “Rooftop Space”). 

10. Standard Tenant Improvement Package Specifications. Tenant hereby acknowledges that the Tenant Improvements are subject to
the specifications set forth in the Tenant Improvement Construction Manual dated August 22, 2018. 

  

					
		  	 EXHIBIT B

-12-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 SCHEDULE 1 

BASE BUILDING “WARM SHELL” DELIVERY CONDITION 

 

  

					
		  	 SCHEDULE 1

-1-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

			
	

	  	

 The Cove at Oyster Point 

Building 5 
 181 Oyster Point Boulevard 

South San Francisco, CA 94080 
 Warm Shell Landlord Delivery
Condition 
  

			
	DESCRIPTION
	
	 SITEWORK

	1.	  	Exterior hardscape and landscape, including site lighting, perimeter sidewalks, street curbs, miscellaneous site furnishings, and bio-retention basins
	2.	  	Surface parking lot
	3.	  	Bike lockers located in campus site and podium parking garage for pro rata allocation amongst Tenants
	4.	  	Campus electrical vehicle charging stations for pro rata allocation amongst Tenants
	5.	  	Exterior amenities space including all hardscape and landscape, lighting, and recreational infrastructure (volleyball/basketball sport court, bocce ball, trellis, 2nd floor
root terrace above Building 6 garage)
	6.	  	Bus stop wind screens for local commuter shuttle service
	7.	  	Service yard foundation, structure, covered enclosure, and waterproofing for trash containers and dedicated nitrogen storage area for allocation amongst tenants in multiple buildings subject to landlord review and
approval
	8.	  	Foundation and enclosure for Landlord provided diesel powered emergency generator
	9.	  	Loading dock with at-grade shipping/receiving area with one (1) hydraulic scissor lift
	
	 STRUCTURE

	1.	  	Pile supported structural slab-on-grade foundation system consisting of steel-reinforced concrete auger-cast piles, pile caps, and horizontal grade beams
	2.	  	Steel superstructure consisting of steel columns, girders, beams, and concrete slab on composite metal deck, with live load capacity of 125 psf (reducible)
	3.	  	Type IB construction, code required primary structural fireproofing
	4.	  	Slab edge fire safing
	5.	  	Lateral seismic system utilizing buckling-restrained braced frames. Importance factor is 1.0
	6.	  	Roof deck framing with live load capacity of 20 psf
	7.	  	Mechanical platform and roof penthouse with live load capacity of 50 psf
	8.	  	Roof screen
	9.	  	Floor to floor height of 17’, all floors (podium at 14’)
	10.	  	Framed openings for Base Building utility risers
	11.	  	Stairs and stair enclosures per code requirements, including enclosure doors, handrails, and guardrails. Root penthouse access for one (1) set of stairs
	12.	  	Window washing davit bases and arms

  
 

 
 The Cove at Oyster Point – Warm Shell Landlord Delivery Conditions: Building 5 – V3.0 August 28, 2018 

  

					
		  	 SCHEDULE 1

-2-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

			
	

	  	

  

			
	DESCRIPTION
		
	13.	  	Miscellaneous metals items and/or concrete pads for Base Building equipment
	
	 ROOFING

	1.	  	60 MIL single-ply thermoplastic polyolefin (TPO) white or gray roof membrane
	2.	  	Rigid insulation, flashing, and sealants
	3.	  	Roofing penetrations for Base Building equipment/systems
	4.	  	Walkway pads along roof perimeter, outside of screened area
	
	 EXTERIOR

	1.	  	Non Load-bearing glazed aluminum curtain wall and glass fiber reinforced concrete (GFRC) panel building enclosure system
	2.	  	Building entrances and openings
	3.	  	Freight elevator access in Podium
	4.	  	Telescoping gate at loading dock area
	
	 COMMON AREAS

	1.	  	Podium parking area with card reader controlled lift gate and roll-up doors
	2.	  	Build-out of Main Lobby
	3.	  	Stair enclosures painted at all building levels
	4.	  	Two (2) B-Occupancy Chemical Storage Rooms with 1-hour fire rated assembly, depressed pit (18”), and 100% outside air ventilation 900 cfm total for each room.
	5.	  	Main Electrical Room
	6.	  	Emergency Electrical Room
	7.	  	Domestic Pump Room
	8.	  	Fire Booster Pump Room
	9.	  	Elevator Control Room
	10.	  	Telecommunications Main Point of Entry (MPOE) Room
	11.	  	Service Yard/Loading Dock Area, including space for trash enclosure, nitrogen storage (for nitrogen use only; allocation subject to Landlord review approval), and generator enclosure
	12.	  	Amenities Space including food service, fitness center, and recreational area (located in Building 3)
	13.	  	Roof Terrace space (located above Building 6 podium parking)
	
	 ELEVATORS

	1.	  	Two (2) passenger elevators; 3,500 lbs., 350 fpm
	2.	  	One (1) freight elevator; 5,000 lbs., 200 fpm
	3.	  	Recessed elevator pits for three (3) elevators
	4.	  	Seismic restraints inside freight elevator
	5.	  	EPS Express Priority Service at freight elevator
	
	 TENANT AREAS

	1.	  	Restroom Cores: one (l) set per floor including Men’s and Women’s Restrooms with (1) ADA shower each with bench and lockers, ceramic tile floors and wet walls, solid surface countertops, floor mounted metal partitions,
hard lid ceiling, down lights and ADA low-flow plumbing fixtures
	2.	  	Janitor Closet – one (1) per floor

  
 

 
 The Cove at Oyster Point – Warm Shell Landlord Delivery Conditions: Building 5 – V3.0 August
28, 2018 

  

					
		  	 SCHEDULE 1

-3-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

			
	

	  	

  

			
	DESCRIPTION
		
	3.	  	Stud wall framing at restroom core to underside of slab
	4.	  	Partial fire-rated assembly at restroom core to 6” above ceiling
	5.	  	Electrical Room – one (1) per floor consisting of concrete floor, unfinished drywall and taped walls, no ceiling
	6.	  	Intermediate Distribution Frame (IDF) Room – one (1) per floor consisting of concrete floor, unfinished drywall and taped walls, no ceiling
	7.	  	Landlord-maintained retractable davit arms stored in ground floor storage room.
	8.	  	Freight elevator lobby on floors 2-5
	9.	  	Finishes at common corridors on floors with multiple Tenants
	10	  	Shaft enclosures for Base Building system risers
	
	 FIRE PROTECTION

	1.	  	Wet fire protection system: risers, distribution piping, and sprinkler heads for core areas
	2.	  	Primary distribution and sprinkler heads adequate for “Ordinary Hazard Group 2” for core and shell coverage
	3.	  	Fire extinguisher cabinets at core areas
	4.	  	Fire safing at Base Building vertical penetrations, including penetrations for mechanical, electrical, and plumbing systems
	5.	  	Fire booster pump room including fire department connection, alarm valve and fire sprinkler booster pump.
	
	 PLUMBING

	1.	  	Building storm and overflow drainage system, including site underground storm sewer system and connection to storm sewer mains
	2.	  	Sand/Oil separator with connection to street
	3.	  	Domestic water service with backflow prevention and Base Building risers to Tenant spaces
	4.	  	Domestic water booster pump
	5.	  	Building lab waste consisting of underslab piping under podium parking, risers, and stubs in Tenant space
	6.	  	Lab waste sewer connection to sanitary sewer, lab waste sampling port at connection
	7.	  	Water heater on 2nd and 4th floor, inside Janitors Closet serving core Restrooms.
	8.	  	Domestic sanitary sewer connection to street
	9.	  	Main water meter and irrigation meter
	10.	  	Core restroom plumbing fixtures compliant with accessibility requirements
	
	 NATURAL GAS

	1.	  	Medium pressure natural gas service to Building
	2.	  	Natural gas riser to the roof and service to Base Building boilers
	
	 HEATING, VENTILATION, AIR CONDITIONING

	1.	  	Two (2) 109,000 cfm 100% outside air roof mounted air handlers serving Tenant lab spaces, allocation to Tenant space: standard 27,250 cfm per unit per floor (connected to standby power)

  
 

 
 The Cove at Oyster Point – Warm Shell Landlord Delivery Conditions: Building 5 – V3.0 August 28, 2018 

  

					
		  	 SCHEDULE 1

-4-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

			
	

	  	

  

			
	DESCRIPTION
		
	2.	  	Two (2) 42,000 cfm supply/return root mounted air handlers serving Tenant office spaces, allocation to Tenant space: standard 10,500 cfm per unit per floor
	3.	  	Three (3) 3,300 MBH input gas fired hot water boilers (connected to standby power)
	4.	  	Two (2) 420 ton centrifugal chillers
	5.	  	 Chilled Water Pipe Risers, stubbed into tenant space.

Chilled Water (Per Floor) supply & return future capped Valves 2”

Chilled water stub outs not meant for 24/7 systems

	6.	  	Cooling only split system for base building MPOE Room
	7.	  	Two (2) 420 ton cooling towers
	8.	  	Secondary mechanical equipment, including pumps, roof ducting, piping, valves, manifolds, etc. to support Base Building mechanical systems
	9.	  	Hot water (Per Floor) Supply & return future capped valves 3”
	10.	  	Reheat coils within building lobby
	11.	  	Vertical supply air duct risers
	12.	  	Vertical return air duct risers
	13.	  	Horizontal supply air distribution: ducting, VAV terminals, equipment connections, insulation, air terminals, dampers, hangers, etc. within building lobby
	14.	  	Two (2) roof mounted dilution lab exhaust fan systems with 109,000 cfm capacity each, allocation to Tenant space: (connected to standby power)
	15.	  	Restroom exhaust for Base Building restrooms
	16.	  	Ventilation system for Base Building Electrical Room
	17.	  	Exhaust fan, side wall grille supply, and fire smoke dampers for ventilation of Base Building Electrical Rooms on each floor
	18.	  	Building Management System (BMS) for core area and Landlord infrastructure
	
	 ELECTRICAL

	1.	  	Site campus medium voltage distribution system with connection to PG&E grid
	2.	  	5,000 amp 480/277V Base Building substation with underground primary feeder to campus main switchgear
	3.	  	One (1) 1500 kW diesel standby power generator
	4.	  	Standby power 1,200amps 480/277V bus duct riser providing 300amps per floor
	5.	  	Ground bar per floor connecting back to the Main Electric Room
	6.	  	Normal and Standby power available at roof for tenant utility loads
	7.	  	Automatic transfer switch for Tenant load
	8.	  	Lighting and power distribution for core areas separated from tenant loads
	9.	  	Base Building common area life safety emergency lighting/signage
	10.	  	Two (2) 4” sleeves in IDF rooms for future Tenant cell network infrastructure.
	11.	  	Emergency Responder Radio Coverage System (ERRCS) consisting of head-end system, roof-mounted antenna, and 2” conduit risers in stair shafts. No coverage within Tenant premises.

  
 

 
 The Cove at Oyster Point – Warm Shell Landlord Delivery Conditions: Building 5 – V3.0 August 28, 2018 

  

					
		  	 SCHEDULE 1

-5-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

			
	

	  	

  

			
	DESCRIPTION
	
	 FIRE ALARM

	1.	  	Base Building fire alarm system with devices in core areas (connected to standby power)
	2.	  	Fire Alarm Termination Cabinet (FATC) within each Electrical Room
	
	 TELEPHONE/DATA

	1.	  	Underground local fiber optic & telephone conduit only to Main Point of Entry (MPOE) Room
	2.	  	Two (2) 4” conduit risers from MPOE to Intermediate Distribution Frame (IDF) Room on each floor
	3.	  	Sleeves for future conduit riser from IDF Rooms to the roof; Landlord approval required for usage
	4.	  	Underground conduit to be shared with base building uses consisting of two (2) 4” conduits for campus intertie, two (2) 4” conduits for AT&T; two (2) 4” conduits for security and (1) 4” & (1) 2”
conduit for Comcast.
	
	 SECURITY

	1.	  	Card access at Building entries
	2.	  	Video surveillance and intercom system at entrance and receiving doors of the Building
	3.	  	Main Lobby desk for future security operations. Security guard scope TBD

  
 

 
 The Cove at Oyster Point – Warm Shell Landlord Delivery Conditions: Building 5 – V3.0 August 28, 2018 

  

					
		  	 SCHEDULE 1

-6-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 SCHEDULE 2 

LEED REQUIREMENTS 
  

					
	

	  		  	

 LEADERSHIP IN ENERGY AND ENVIRONMENTAL DESIGN (LEED) 

 

	1.	 BASE BUILDING LEED CERTIFICATION 

The following is a list of LEED pre-requisites and credits that all Tenants are required to meet for their associated Tenant-occupied spaces beyond the
current Core and Shell project scope, to maintain the Core and Shell LEED Silver Certification. By signing the Lease, Tenants are agreeing to comply with all of the outlined requirements. 

 

	 	•	 	 Location & Transportation Credit, Reduced Parking Footprint 

 

	 	•	 	 Projects must achieve a minimum of 40% reduction from the base ratios. 

 

	 	•	 	 Location & Transportation Credit, Bicycle Facilities 

 

	 	•	 	 Long term bicycle storage facilities shall cater to at least 5% of regular building occupants, but no fewer than
2 storage spaces. Short term bicycle storage will include a minimum of 2 bicycle parking spaces for every 5000 sq.ft. 

  

	 	•	 	 Water Efficiency Credit, Indoor Water Use Reduction 

 

	 	•	 	 All toilets in the core or those that are Tenant-installed shall be dual-flush toilets or
“high-efficiency,” using 1.28 gallons per flush (gpf) or less. 

  

	 	•	 	 All urinals shall be waterless or ultra low-flow e.g., 0.125 gpf or less. 

 

	 	•	 	 Bathroom faucets are required to have flow restrictors limiting flow to .5 gallons per minute (gpm).

  

	 	•	 	 Kitchen and breakroom faucets to allow 1.8 gpm. 

 

	 	•	 	 All newly installed toilets, urinals, private lavatory faucets, and showerheads that are eligible for labeling
must be WaterSense labeled 

  

	 	•	 	 Energy and Atmosphere Prerequisite, Minimum Energy Performance, and Credit, Optimize Energy Performance

  

	 	•	 	 Envelope must meet the following requirements: 

 

	 	•	 	 Walls: U = 0.082 

  

	 	•	 	 Roof: U = 0.039 

  

	 	•	 	 Curtain Glazing: U = 0.27, SHGC = 0.29 (Viracon) 

 

	 	•	 	 Mechanical (Based on B3) systems must comply with the following: 

 

	 	•	 	 Chiller Efficiency: 0.549 kw/ton 

 

	 	•	 	 Boiler Efficiency: 93% 

 

	 	•	 	 Plumbing (Based on B3) must comply with the following: 

 

	 	•	 	 Water heater efficiency: 96% 

 

	 	•	 	 Lighting recuirements are as follows: 

 

	 	•	 	 Office Spaces > 250 ft2: 0.75 w/sf 

 

	 	•	 	 Office Spaces < 250 ft2: 1.0 w/sf 

 

	 	•	 	 Lab Spaces: 1.4 w/sf 

  

	 	•	 	 Energy and Atmosphere Credit, Enhanced Refrigerant Management 

  

					
		  	 SCHEDULE 2

-7-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

					
	

	  		  	

  

	 	•	 	 Tenants should specify HVAC systems that minimize refrigerant impact by avoiding refrigerants entirety or using
systems that have an ozone depletion potential (ODP) of zero and a global warming potential (GWP) of less than 50 

  

	 	•	 	 Energy and Atmosphere Credit, Advanced Energy Metering 

 

	 	•	 	 Install new or use existing tenant-level energy meters to provide tenant-level data representing total tenant
energy consumption (electricity, natural gas, chilled water, steam, fuel oil, propane, biomass, etc.). Utility-owned meters are acceptable. 

  

	 	•	 	 Commit to sharing with USGBC the resulting energy consunmption data and electrical demand data (if metered) for a
five-year period beginning on the date the project accepts LEED certification. At a minimum, energy consumption must be tracked at one-month intervals. 

  

	 	•	 	 Indoor Environmental Quality Prerequisite, Minimum Indoor Air Quality (IAQ) Performance 

 

	 	•	 	 Tenant-installed mechanical ventilation systems must meet the requirements of ASHRAE 62.1-2010 Section 4-7.

  

	 	•	 	 Indoor Environmental Quality Credit, Enhanced Indoor Air Quality Strategies 

 

	 	•	 	 All rooms that contain chemicals or pollutants (such as copy rooms, photo labs, laundry, and janitorial rooms)
must be built with deck-to-deck full-height walls and self-closing doors, separate ventilation systems with minimum .50 cfm/sqft exhaust fans, and containment drains for appropriate disposal of hazardous liquids 

 

	 	•	 	 Walk off mats are installed at all building main entrances as part of the core and shell scope.

  

	 	•	 	 744331.07/WLA 

  

	 	•	 	 375072-0000l/12-9-15/gin/gin 

 

	 	•	 	 Tenants must also install MERV-13 filters for all return and outside air intakes in regularly occupied
mechanically ventilated spaces 

  

	 	•	 	 For mechanical ventilation systems that predominantly serve densely occupied spaces (those with a design occupant
density greater than or equal to 25 people per 1000 sq. ft), Tenants shall install a CO2 sensor within each densely occupied space. 

  

	 	•	 	 For all other mechanical ventilation systems, provide an outdoor airflow measurement device capable of measuring
the minimum outdoor airflow rate at all expected system operating conditions within 15 percent of the design minimum outdoor air rate. 

  

	 	•	 	 Indoor Environmental Quality Credit, Thermal Comfort 

 

	 	•	 	 HVAC design must meet requirements of ASHRAE 55-2010, specifically in reference to air temperature, radiant
temperature, humidity, and air speed 

  

	2.	 TENANT IMPROVEMENT LEED CERTIFICATION 

All Tis are required to achieve and obtain ID+C LEED Silver certification. 

  

					
		  	 SCHEDULE 2

-8-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 SCHEDULE 3 

TIME DEADLINES 
  

 
 GBT TI 
 The Cove –
Building 5, Floors 2-5 
 181 Oyster Point Blvd. 
 South San
Francisco, CA 
 Updated 8/23/18 
 Tenant
Improvement Milestone Schedule 
  

			
	02/01/2019	  	TI Design Commencement
		
	03/25/2019	  	Tenant Submission of Final Equipment List
		
	04/01/2019	  	Tenant Approval of Schematic Plans
		
	05/31/2019	  	Tenant Submission of HMIS
		
	06/14/2019	  	Tenant Approval of Final TI Working Drawings
		
	06/14/2019	  	Anticipated Submittal of Permit Documents (Final TI Working Drawings) to City
		
	07/05/2019	  	Tenant Approval of Final Project Budget
		
	07/19/2019	  	Anticipated Construction Commencement
		
	03/15/2020	  	Anticipated Substantial Completion/Occupancy

  

  

					
		  	 SCHEDULE 3

-1-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 SCHEDULE 4 

ROOFTOP SPACE 
  

 

  

					
		  	 SCHEDULE 4

-1-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 EXHIBIT C 

FORM OF AMENDMENT FOR TENANT MAINTENANCE RESPONSIBILITIES 

AMENDMENT TO LEASE 

This _____________ AMENDMENT TO LEASE (“Amendment”) is made and entered into as of ____________ ___, 20___, by and between
HCP OYSTER POINT III LLC, a Delaware limited partner (“Landlord”), and GLOBAL BLOOD THERAPEUTICS, INC., a Delaware corporation (“Tenant”). 

R E C I T A L S : 

A. Landlord and Tenant are parties to that certain Lease dated March 17, 2017, (the “Lease”), as amended by that certain
First Amendment to Lease dated _______, 2018 (the “First Amendment”) pursuant to which Tenant leases 164,150 rentable square feet of space (the “Premises”) comprising the entirety of the building located at 181
Oyster Point Boulevard, South San Francisco, California 94080 (the “Substitute Building”). The Original Lease and the First Amendment are collectively, the “Lease.” 

B. Landlord and Tenant desire to amend the Lease on the terms and conditions set forth in this Amendment. 

A G R E E M E N T : 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Terms.
All capitalized terms when used herein shall have the same respective meanings as are given such terms in the Lease unless expressly provided otherwise in this Amendment. 

2. Repairs. Effective as of _______, 20___, Article 7 of the Original Lease is deleted in its entirety and replaced with the following:

 “7. REPAIRS 

7.1 Tenant Repair Obligations. Tenant shall, throughout the Term, at its sole cost and expense, maintain, repair, or replace as
required, the Premises and Building and every part thereof in a good standard of maintenance, repair and replacement as required, and in good and sanitary condition, all in accordance with the standards of First Class Life Sciences Projects,
except for Landlord Repair Obligations, whether or not such maintenance, repair, replacement or improvement 

  

					
		  	 EXHIBIT C

-1-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
is required in order to comply with applicable Laws (“Tenant’s Repair Obligations”), including, without limitation, the following: (1) interior glass, windows, window frames,
and window casements (including the repairing, resealing, cleaning and replacing of interior windows); (2) interior doors, door frames and door closers; (3) interior lighting (including, without limitation, light bulbs and ballasts); (4) the
plumbing, sewer, drainage, electrical, fire protection, life safety and security systems and equipment, existing heating, ventilation and air-conditioning systems, and all other mechanical, electrical and
communications systems and equipment (collectively, with the elevator in the Building, the “Building Systems”), including without limitation (i) any specialty or supplemental Building Systems installed by or for Tenant and
(ii) all electrical facilities and equipment, including lighting fixtures, lamps, fans and any exhaust equipment and systems, electrical motors and all other appliances and equipment of every kind and nature located in, upon or about the
Premises; (5) all communications systems serving the Premises; (6) all of Tenant’s security systems in or about or serving the Premises; (7) Tenant’s signage; (8) interior demising walls and partitions (including
painting and wall coverings), equipment, floors, and any roll-up doors, ramps and dock equipment; and (9) the Building HVAC system and equipment. Tenant shall additionally be responsible, at Tenant’s
sole cost and expense, to furnish all expendables, including light bulbs, paper goods and soaps, used in the Premises, and, to the extent that Landlord notifies Tenant in writing of its intention to no longer arrange for such monitoring, cause the
fire alarm systems serving the Premises to be monitored by a monitoring or protective services firm approved by Landlord in writing. 
 7.2
Service Contracts. Subject to the Landlord Repair Obligations, all Building Systems, (other than the elevator), including HVAC, main electrical, plumbing and fire/life-safety systems, shall be maintained, repaired and replaced by Tenant
(i) in a commercially reasonable first-class condition, (ii) in accordance with any applicable manufacturer specifications relating to any particular component of such Building Systems, (iii) in accordance with applicable Laws. To
perform such work, Tenant shall contract with qualified, experienced professional third party service companies (a “Service Contract”). Tenant shall regularly, in accordance with commercially reasonable standards, generate and maintain
preventive maintenance records relating to each Building’s mechanical and main electrical systems, including life safety and the central plant (“Preventative Maintenance Records”). In addition, upon Landlord’s request, Tenant
shall deliver a copy of all current Service Contracts to Landlord and/or a copy of the Preventative Maintenance Records. 
 7.3
Landlord’s Right to Perform Tenant’s Repair Obligations. Tenant shall notify Landlord in writing at least ten (10) business days prior to performing any Tenant’s Repair Obligation which may have a material, adverse effect
on the Building Systems or which is reasonably anticipated to cost more than $100,000.00. Upon receipt of such notice from Tenant, Landlord shall have the right to either (i) perform such material Tenant’s Repair Obligation by delivering
notice of such election to Tenant within ten (10) business days following receipt of Tenant’s 

  

					
		  	 EXHIBIT C

-2-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
notice, and Tenant shall pay Landlord the cost thereof (including Landlord’s reasonable out-of-pocket costs
incurred in connection therewith) within thirty (30) days after receipt of an invoice therefor, or (ii) require Tenant to perform such Tenant’s Repair Obligation at Tenant’s sole cost and expense. If Tenant fails to perform any
Tenant’s Repair Obligation within a reasonable time period after written notice thereof from Landlord, as reasonably determined by Landlord, then Landlord may, but need not, following delivery of notice to Tenant of such election, make such
Tenant Repair Obligation, and Tenant shall pay Landlord the cost thereof, (including Landlord’s reasonable supervision fee) within thirty (30) days after receipt of an invoice therefor. 

7.4 Landlord Repair Obligations. Landlord shall be responsible for repairs to and routine maintenance of (i) the exterior glass,
exterior walls, foundation and roof of the Building, the structural portions of the floors of the Building, including, without limitation, any painting, sealing, patching and waterproofing of exterior walls, and (ii) repairs to the elevator in
the Building and underground utilities, except to the extent that any such repairs are required due to the negligence or willful misconduct of Tenant (the “Landlord Repair Obligations”); provided, however, that if such repairs are due to
the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant’s expense, or, if covered by Landlord’s insurance, Tenant shall only be obligated to pay any deductible in connection therewith. Costs
expended by Landlord in connection with the Landlord Repair Obligations shall be included in Operating Expenses to the extent allowed pursuant to the terms of Article 4, above. Landlord shall cooperate with Tenant to enforce any warranties that
Landlord holds that could reduce Tenant’s maintenance obligations under this Lease. 
 7.5 Tenant’s Right to Make Repairs.
Notwithstanding any provision to the contrary contained in this Lease, if Tenant provides written notice to Landlord of an event or circumstance which requires the action of Landlord under this Lease with respect to repair and/or maintenance
required in the Premises, including repairs to the portions of the Building located within the Premises that are Landlord’s responsibility under Section 7.4 (the “Base Building”), which event or circumstance with respect to the
Base Building materially and adversely affects the conduct of Tenant’s business from the Premises, and Landlord fails to commence corrective action within a reasonable period of time, given the circumstances, after the receipt of such notice,
but in any event not later than thirty (30) days after receipt of said notice (unless Landlord’s obligation cannot reasonably be performed within thirty (30) days, in which event Landlord shall be allowed additional time as is
reasonably necessary to perform the obligation so long as Landlord begins performance within the initial thirty (30) days and diligently pursues performance to completion), or, in the event of an Emergency (as defined below), not later than
five (5) business days after receipt of such notice, then Tenant shall have the right to undertake such actions as may be reasonably necessary to make such repairs if Landlord thereafter fails to commence corrective action within five
(5) business days following Landlord’s receipt of a second written notice from Tenant specifying that Tenant will undertake such actions if Landlord fails to timely do so (provided 

  

					
		  	 EXHIBIT C

-2-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
that such notice shall include the following language in bold, capitalized text: “IF LANDLORD FAILS TO COMMENCE THE REPAIRS DESCRIBED IN THIS LETTER WITHIN FIVE (5) BUSINESS DAYS FROM
LANDLORD’S RECEIPT OF THIS LETTER, TENANT WILL PERFORM SUCH REPAIRS AT LANDLORD’S EXPENSE”; provided, however, that in no event shall Tenant undertake any actions that could materially or adversely affect the Base Building.
Notwithstanding the foregoing, in the event of an Emergency, no second written notice shall be required as long as Tenant advises Landlord in the first written notice of Tenant’s intent to perform such Emergency repairs if Landlord does not
commence the same within such five (5) business day period, utilizing the language required in second notices. If such action was required under the terms of this Lease to be taken by Landlord and was not commenced by Landlord within such five
(5) business day period and thereafter diligently pursued to completion, then Tenant shall be entitled to prompt reimbursement by Landlord of the reasonable
out-of-pocket third-party costs and expenses actually incurred by Tenant in taking such action. If Tenant undertakes such corrective actions pursuant to this
Section 7.3, then (a) the insurance and indemnity provisions set forth in this Lease shall apply to Tenant’s performance of such corrective actions, (b) Tenant shall proceed in accordance with all applicable laws, (c) Tenant
shall retain to perform such corrective actions only such reputable contractors and suppliers as are duly licensed and qualified, (d) Tenant shall effect such repairs in a good and workmanlike and commercially reasonable manner, (e) Tenant
shall use new or like new materials, and (f) Tenant shall take reasonable efforts to minimize any material interference or impact on the other tenants and occupants of the Building. Promptly following completion of any work taken by Tenant
pursuant to the terms of this Section 7.5, Tenant shall deliver a detailed invoice of the work completed, the materials used and the costs relating thereto, and Landlord shall reimburse Tenant the amounts expended by Tenant in connection with
such work, provided that Landlord shall have the right to reasonably object if Landlord claims that such action did not have to be taken by Landlord pursuant to the terms of this Lease or that the charges are excessive (in which case Landlord shall
pay the amount it contends would not have been excessive). For purposes of this Section 7.5, an “Emergency” shall mean an event threatening immediate and material danger to people located in the Building or immediate, material damage
to the Building, Base Building, or creating a realistic possibility of an immediate and material interference with, or immediate and material interruption of a material aspect of Tenant’s business operations.” 

3. Generator. Effective as of _______, 20___, Section 6.5 of the Original Lease is deleted in its entirety and replaced with the
following: 
 “6.5 Generator. Tenant shall have the right to connect to the Building
back-up generator, which Landlord shall install as part of Landlord’s Work (the “Generator”), for Tenant’s Share of the Generator’s capacity available to tenants of the Building
to provide back-up generator services to the Premises. During the Lease Term, Tenant shall maintain such Generator at Tenant’s sole cost and expense. Notwithstanding the foregoing, Landlord shall not be
liable for any damages whatsoever resulting from any failure in operation of the Generator, or the 

  

					
		  	 EXHIBIT C

-4-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]

 
failure of the Generator to provide suitable or adequate back-up power to the Premises, including but not limited to, loss of profits, loss of rents or
other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, or loss to inventory, scientific research, scientific experiments, laboratory animals, products, specimens, samples, and/or scientific,
business, accounting and other records of every kind and description kept at the Premises and any and all income derived or derivable therefrom. Tenant’s obligations with respect to the Premises, including the insurance and indemnification
obligations contained in Article 10, below, shall apply to Tenant’s use of the Generator and Tenant shall carry industry standard Boiler and machinery insurance covering the Generator. Tenant shall maintain all
required permits in connection with the Generator throughout the Lease Term. Tenant shall leave the Generator in place upon the expiration or earlier termination of this Lease, surrender the Generator (and shall transfer to Landlord all permits
maintained by Tenant in connection with the Generator during the Lease Term) concurrent with the surrender of the Premises to Landlord as required hereunder in good operating and working order, with all permits current.” 

4. No Further Modification. Except as specifically set forth in this Amendment, all of the terms and provisions of the Lease shall
remain unmodified and in full force and effect. 
 IN WITNESS WHEREOF, this Amendment has been executed as of the day and year first above
written. 
  

									
	LANDLORD:	 		 	TENANT:
			
	HCP OYSTER POINT III LLC,
a Delaware limited liability company	 		 	GLOBAL BLOOD THERAPEUTICS, INC.,
a Delaware corporation
					
	By:	 	   
	 		 	By:	 	   

					
		 	Name:
                                         
                                         
	 		 		 	Name:
                                         
                                       

					
		 	Its:
                                         
                                         
    	 		 		 	Its:
                                         
                                         
    

  

					
		  	 EXHIBIT C

-5-
	  	 THE COVE AT OYSTER POINT

[First Amendment]
 [Global Blood
Therapeutics, Inc.]Exhibit 10.1

Execution Copy: August 1, 2013

 

ASSET PURCHASE AGREEMENT

 

ASSET PURCHASE AGREEMENT
(“Agreement”), dated August 1, 2013 (the “Effective Date”), between Mikah Pharma LLC
a limited liability company organized under the laws of the State of Delaware ( “Seller”) and Elite Laboratories,
Inc., a corporation incorporated under the laws of the State of Delaware (“Buyer”). Buyer and Seller are
each “Party” to this Agreement and together constitute the “Parties”.

 

Background

 

Seller owns ANDAs that
it acquired from Actavis, Inc. that was operating under a Consent Decree, a copy of which was provided to Buyer, which may subject
the ANDAs (as defined below) to additional scrutiny before FDA permits the Products (as defined below) to be manufactured elsewhere.
Nevertheless, on the terms and conditions set forth in this Agreement and the Consent Decree, Buyer wishes to purchase from Seller
and Seller wishes to sell to Buyer, the ANDAs.

 

NOW, THEREFORE, in consideration
of the mutual covenants herein contained and for other good and valuable consideration the receipt and adequacy of which are hereby
acknowledged, the Parties hereby agree as follows:

 

DEFINITIONS

 

Definitions

 

All terms not defined below are
defined elsewhere in this Agreement.

 

“Affiliate”
means any Person that directly or indirectly Controls, is Controlled by or is under common Control with another Person. A Person
will be deemed to “Control” another Person if it has the power to direct or cause the direction of the other
Person, whether through ownership of securities, by contract or otherwise.

 

“Agency”
means any governmental regulatory authority or authorities in the United States responsible for granting approval(s), clearance(s),
qualification(s), license(s) or permit(s) for any aspect of the research, development, manufacture, marketing, distribution or
sale of a Product. The term “Agency” includes, but is not limited to, the FDA and the United States Drug Enforcement
Administration.

 

“ANDA(s)” means Abbreviated
New Drug Applications listed in Schedule 1 and all amendments thereto, that have to date been filed with the FDA seeking
authorization and approval to manufacture, package, ship and sell, as more fully defined in 21 C.F.R. Part 314, the Products.

  

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

    		- 1 -	Confidential

     

    

  

“ANDA Technology
and Scientific Materials” means any technological, scientific, chemical or biological materials, trade secrets, know-how,
Intellectual Property, techniques, data, inventions, practices, methods and all other confidential and proprietary technical, research,
development and other applicable business information (whether patented, patentable or otherwise) related to the manufacture, validation,
packaging, release testing, stability and shelf life of the Product, including all Product formulations, in existence and in the
possession of Seller as of the Closing Date.

 

“Assumed Liabilities”
has the meaning set forth in Section 2.3.

 

“Bill of Sale”
means a bill of sale to be delivered by Seller to Buyer effective on the Closing Date, substantially in the form of Exhibit
A.

 

“Business
Day” means any day other than a Saturday, Sunday or other day on which banks in New York, New York are permitted or required
to close by law or regulation.

 

“Buyer”
has the meaning set forth in the preamble.

 

“Buyer Indemnified
Parties” has the meaning set forth in Section 8.2.

 

Calendar Quarter”
means the three month period ending on the last day of each of March, June, September and December.

 

“Closing”
and “Closing Date” have the meanings given such terms in Section 3.1.

 

“Development”
means all preclinical and clinical drug development activities, including test method development and stability testing, toxicology,
bioequivalency, formulation, process development, manufacturing scale-up, development-stage manufacturing, quality assurance/quality
control development, statistical analysis and report writing, conducting clinical trials for the purpose of obtaining any and all
approvals, licenses, registrations or authorizations from any Agency necessary for the manufacture, use, storage, import, export,
transport, promotion, marketing and sale of the Products, Product approval and registration, and regulatory affairs related to
the foregoing. “Develop” means to engage in Development.

 

“Effective
Date” has the meaning set forth in the preamble.

 

“Encumbrance”
means any mortgage, charge, lien, security interest, easement, right of way, pledge or encumbrance of any nature whatsoever.

 

“Excluded
Liabilities” has the meaning set forth in Section 2.3.

 

“FDA”
means the United States Food and Drug Administration.

 

“Governmental
Entity” means any court, administrative agency, department or commission or other governmental authority or instrumentality,
whether U.S. or non-U.S.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 2 -	Confidential

     

    

  

“Governmental
Rule” means any law, judgment, order, decree, statute, ordinance, rule or regulation issued or promulgated by any Governmental
Entity or Agency.

 

“Intellectual
Property” has the meaning set forth in Section 4.7.

 

“Liabilities”
means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, or
determined or determinable, including those arising under any law, action or governmental order and those arising under any contract,
agreement, arrangement, commitment or undertaking, or otherwise.

 

“Losses”
means, collectively, any and all damages, losses, taxes, Liabilities, claims, judgments, penalties, costs and expenses (including
reasonable legal fees and expenses).

 

“Material
Adverse Effect” means an effect which is material and adverse to the Purchased Assets taken as a whole, but does not
include: (i) any adverse effect due to changes in conditions generally affecting (A) the healthcare industry or (B) the United
States economy as whole, (ii) any change or adverse effect caused by, or relating to, the announcement of this Agreement and the
transactions contemplated by this Agreement or (iii) any adverse effect due to legal or regulatory changes.

 

“Mutual Confidential
Disclosure Agreement” means the Mutual Confidential Disclosure Agreement entered into by the parties dated May 18, 2010.

 

“Person”
means any individual, corporation, partnership, limited liability company, joint venture, trust, business association, organization,
Governmental Entity or other entity.

 

“Product(s)”
means the pharmaceutical or products now or hereafter described in the ANDAs.

 

“Purchase
Note” has the meaning set forth in Section 2.1.

 

“Purchase
Price” has the meaning set forth in Section 2.1.

 

“Purchased
Assets” has the meaning set forth in Section 2.2.

 

“Security
Agreement” has the meaning set forth in Section 2.1.

 

“Territory”
means the United States and its territories, possessions, and commonwealths, including Puerto Rico.

 

“United States”
or “U.S.” or “U.S.A.” means the United States of America.

 

Interpretation

 

When used in this Agreement
the words “include”, “includes” and “including” will be deemed to be followed by the words
 “without limitation.” Any terms defined in the singular will have a comparable meaning when used in the plural, and
vice-versa.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 3 -	Confidential

     

    

  

Currency

 

All currency amounts
referred to in this Agreement are in United States Dollars, unless otherwise specified.

 

SALE AND PURCHASE OF ASSETS

 

Purchase and Sale

 

Upon the terms and
subject to the conditions of this Agreement, on the Closing Date, upon payment of the $10,000,000 purchase price (the “Purchase
Price”) in the form of a Senior Secured Convertible Promissory Note ( the “Purchase Note”), a copy
of the form of which is attached hereto as Exhibit B, payment and performance of which by Buyer is secured in accordance
with an ANDA Security Agreement in the form attached hereto as Exhibit C (the “Security Agreement”),
and by this reference incorporated herein, Seller will sell, assign, transfer, convey and deliver to Buyer, and Buyer will purchase,
acquire and accept, all right, title and interest, within the Territory, of Seller in, to and under the Purchased Assets.

 

Purchased Assets

 

The term “Purchased
Assets” means the following properties, assets and rights of whatever kind and nature, tangible or intangible, of Seller
existing on the Closing Date that relate solely and exclusively to the ANDAs and any testing, data, studies, and formulations created
in connection therewith including but not limited to: (i) the ANDAs,
(ii) any correspondence with the FDA in Seller’s files with respect to the ANDAs, (iii) the right of reference to
the Drug Master Files, as set forth in the ANDAs; (iv) the ANDA Technology and Scientific Materials; (v) all rights to manufacture,
sell or otherwise exploit any products resulting therefrom including all rights to revenues generated therefrom; and (vi) a royalty
free limited license to use any ANDA Technology and Scientific Materials which is common to the Product and any other product of
Seller, but only for Buyer’s use in connection with the manufacture of any Product.

 

Assumption of
Certain Liabilities and Obligations

 

From and after the Closing,
Buyer will assume, be responsible for and pay, perform and discharge when due only those Liabilities in connection with the Purchased
Assets, the use thereof and the later sale of any Product by Buyer arising from and after the Closing Date and only with respect
to events, conditions, actions or circumstances first arising after the Closing Date, including but not limited to (i) Liabilities
arising from any patent or trademark infringement claim or lawsuit brought by any Third Party, (ii) any product liability claim,
and (iii) Liabilities arising from FDA or any other Governmental Entity action or notification after the Closing Date (collectively,
the “Assumed Liabilities”). Notwithstanding the foregoing, Buyer will not assume or be liable for any Liabilities
arising in connection with the Product and the Purchased Assets manufactured prior to the Closing Date, including Liabilities resulting
from Third Party agreements of Seller or its Affiliates and Third Party claims arising out of acts or omissions of Seller prior
to Closing Date (collectively, the “Excluded Liabilities”).

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

    		- 4 -	Confidential

     

    

  

CLOSING

 

Closing Date

 

The closing of the
sale and transfer of the Purchased Assets (the “Closing”) will take place at the offices of either Buyer or
Seller or by fax, electronic delivery or mail, or other place as mutually agreed to by the Parties. The Closing shall take place
on the Effective Date or first Business Day following the execution of this Agreement; provided, however, all of
the conditions to each Party’s obligations under this Article have been satisfied or waived, or at such other time and date
as will be mutually agreed to by the Parties hereto (such date of the Closing being hereinafter referred to as the “Closing
Date”).

  

Intentionally left blank.

 

Conditions to Obligations
of Buyer

 

The obligation of Buyer
to purchase the Purchased Assets from Seller is subject to the satisfaction on and as of the Closing of each of the following conditions,
unless waived by Buyer:

 

Representations.
The representations and warranties of Seller set forth in this Agreement will be true and correct as of the Closing as though made
on and as of the Closing, except to the extent such representations and warranties relate to an earlier date (in which case such
representation and warranties will be true and correct as of such earlier date).

 

Performance of Obligations
of Seller. Seller will have performed or complied in all material respects with all obligations, conditions and covenants required
to be performed by it under this Agreement at or prior to the Closing.

 

Closing Deliveries.
Seller will have executed and delivered to Buyer, dated as of the Closing Date, the (i) Bill of Sale, and (ii) a “Transfer
of Ownership” letter to the FDA, relating to each of the ANDAs, as prescribed in 21 CFR 314.72, and shall deliver to Buyer
a certificate of the Secretary of State or other applicable Governmental Authority certifying the good standing of Seller in its
jurisdiction of organization as of a date within seven days of the Closing Date.

 

ANDAs. As further
described in Section 6.2, Seller will deliver the ANDAs to Buyer.

 

No Government Rule enacted,
entered, promulgated, enforced or issued by any Governmental Entity, Agency, or other legal restraint or prohibition shall be pending,
threatened or in effect, which would (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause
any of the transactions contemplated by this Agreement to be rescinded following consummation or (iii) affect adversely the right
of Purchaser to own or exploit the Purchased Assets.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 5 -	Confidential

     

    

  

Conditions to the Obligations
of Seller

 

The obligations of
Seller to sell, assign, convey, and deliver the Purchased Assets, or to cause the Purchased Assets to be sold, assigned, conveyed
or delivered, as applicable, to Buyer are subject to the satisfaction on and as of the Closing of each of the following conditions,
unless waived by the Seller:

 

Representations and
Warranties. The representations and warranties of Buyer set forth in this Agreement will be true and correct in all material
respects as of the Closing as though made on and as of the Closing, except: (i) to the extent such representations and warranties
expressly relate to an earlier date (in which case such representations and warranties will be true and correct as of such earlier
date) and (ii) for breaches of representations and warranties as to matters that individually or in the aggregate would not materially
interfere with Buyer’s performance of its obligations hereunder; and

 

Closing Deliveries.
Buyer shall have delivered to Seller, (i) an original executed copy of the Purchase Note and Security Agreement, and (ii) a certificate
of the Secretary of State or other applicable Governmental Authority certifying the good standing of Buyer in its jurisdiction
of organization as of a date within seven days of the Closing Date.

 

REPRESENTATIONS AND WARRANTIES OF
SELLER

 

As of each of the Effective
Date and Closing Date, Seller hereby represents and warrants to Buyer as follows:

 

Seller Organization; Good
Standing; Business

 

Seller is a limited
liability company, duly organized, validity existing and in good standing under the laws of the State of Delaware. Seller has the
requisite power and authority to own the Purchased Assets and to carry on its business as currently conducted. Seller is duly qualified
to conduct business as a foreign limited liability company and is in good standing in each jurisdiction where the nature of the
business conducted by it makes such qualification necessary, except where the failure to do so qualify or be in good standing would
not have a Material Adverse Effect. Seller, in the ordinary course of its business, regularly acquires and sells ANDAs.

 

Authority; Execution and
Delivery

 

Seller has the requisite
limited liability company power and authority to enter into this Agreement and to consummate the transaction contemplated. The
execution and delivery of this Agreement by Seller and the consummation of the transactions contemplated have been validly authorized.
This Agreement has been executed and delivered by Seller and, assuming the due authorization, execution and delivery of this Agreement
by Buyer, will constitute the legal and binding obligation of Seller, enforceable against it in accordance with its terms, subject
to applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors’
rights generally from time to time in effect and to general principles of equity (including concepts of materiality, reasonableness,
good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 6 -	Confidential

     

    

  

Consents; No Violation,
Etc.

 

The execution and delivery
of this Agreement do not, and the consummation of the transactions contemplated hereby and the compliance with the terms hereof
will not: (i) violate any Governmental Rule applicable to Seller, (ii) conflict with any provision of the certificate of incorporation
or by-laws or certificate of formation or operating agreement (or similar organizational document) of Seller, (iii) result in a
violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right
of termination, cancellation or acceleration) under, or result in the creation of any Encumbrance upon any of the Purchased Assets
(other than those imposed by the Security Agreement) under any of the terms, conditions or provisions of, any contract, agreement,
plan, understanding, undertaking, commitment or arrangement, whether written or oral, any note, bond, mortgage, indenture, lease,
license, deed of trust, loan, or other agreement, instrument or obligation to which Seller is a party or by which Seller or any
of the Purchased Assets may be bound, (iv) to the knowledge of Seller, violate any rights of any non-party, or (v) require any
approval, authorization, consent, license, exemption, filing or registration with any court, arbitrator or Governmental Entity,
except, with respect to the foregoing clauses (i) and (iii), for such violations or conflicts which would not have a Material Adverse
Effect or materially interfere with Seller’s performance of its obligations hereunder or, with respect to the foregoing clause
(v), for such approvals, authorizations, consents, licenses, exemptions, filings or registrations which have been obtained or made
or which, if not obtained or made, would not have a Material Adverse Effect or interfere with Seller’s performance of its
obligations hereunder.

 

Litigation

 

To the knowledge of
Seller, there are no claims, suits, actions or other proceedings pending or threatened in writing against Seller at law or in equity
before or by any Governmental Entity or Agency, including but not limited to federal, state, municipal or other governmental department,
commission, board bureau, agency or instrumentality, domestic or foreign, which may in any way materially adversely affect the
performance of Seller’s obligations under this Agreement or the transactions contemplated hereby. There are no outstanding
claims, suits, actions, judgments, orders, injunctions, decrees or awards against Seller in connection with the Purchased Assets,
this Agreement or the transactions contemplated hereby that have not been satisfied in all material respects.

 

Title to Purchased Assets;
AS IS

 

Seller has good and
valid title to all of the Purchased Assets, as the case may be, free and clear of all Encumbrances. Buyer agrees that it is purchasing
and will take possession of the Purchased Assets in their AS IS condition and that Buyer has been given the opportunity
to conduct such investigations and inspections of the Purchased Assets as it deems necessary or appropriate.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 7 -	Confidential

     

    

  

Purchased Assets AS IS

 

SELLER DOES NOT
MAKE ANY REPRESENTATIONS OR WARRANTIES THAT THE FDA WILL APPROVE ANY FILINGS FOR OR RELATED TO THE ANDAS TRANSFERRED HEREUNDER
OR THAT BUYER WILL EVER BE ABLE TO PRODUCE A COMMERICALLY SALEABLE PRODUCT AS TO THE ANDAS. SELLER FURTHER MAKES NO REPRESENTATIONS
AS TO THE ADEQUACY OR COMPLETENESS OF THE FORMULATION OR OTHER DATA UNDERLYING THE ANDAS AND FURTHER MAKES NO REPRESENTATION AS
TO THE REGULATORY SUFFICIENCY OF THE ANDAS.

 

Intellectual Property. 

 

Seller owns or possesses
adequate and enforceable licenses or other rights to use all “Intellectual Property” as defined below, is not in default
under any such licensing or similar agreement and has not received any notice or has knowledge of conflict with or infringement
(or alleged infringement) of any rights of others. Seller has no notice or knowledge that any of the Intellectual Property is being
infringed upon or appropriated by any third party. The use of any Intellectual Property and other technical or proprietary data
related to the Purchased Assets has not required and does not require the payment of any royalty or similar payment to any person,
firm or corporation, and, immediately following the Closing, Buyer will have good and marketable title thereto, free and clear
of any Encumbrances. “Intellectual Property” means all inventions, improvements, patents, utility models, designs,
trade names, trade dress, trade secrets, trademarks, service marks, copyrights, know-how and other proprietary rights (including
all grants, registrations or applications therefor), and all goodwill associated therewith, relating to the Purchased Assets or
necessary for exploitation of the Purchased Assets, including, without limitation, any trade name, trademark or service mark.

 

Full Disclosure

 

No representation or
warranty of Seller in this Agreement (including the Schedules attached hereto) and no statement of Seller contained in any document
or certificate contemplated by this Agreement, considered as a whole with all other representations, warranties and statements,
contains or will contain any untrue statement of material fact or omits or will omit to state any material fact necessary, in light
of the circumstances under which it was made, in order to make the statements herein or therein not misleading.

 

Exclusive Representations
and Warranties

 

Other than the representations
and warranties set forth in this Article 4, Seller is not making any other representations or warranties, express or implied,
with respect to the Purchased Assets.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 8 -	Confidential

     

    

 

REPRESENTATIONS OF BUYER

 

As of each of the Effective
Date and Closing Date, Buyer hereby represents and warrants to Seller as follows:

 

Buyer’s Organization;
Good Standing

 

Buyer is a corporation
duly organized, validly existing and in good standing under the laws of the State of Delaware. Buyer is not in arrears of any taxes
and is not under investigation by any Governmental Entity. Buyer has requisite corporate power and authority to carry on its business
as it is currently being conducted. Buyer is qualified to conduct business as a foreign corporation and is in good standing in
every jurisdiction where the nature of the business conducted by it makes such qualification necessary, except where the failure
to so qualify or be in good standing would not prevent or materially delay the consummation of the transactions contemplated hereby.

 

Authority; Execution and Delivery

 

Buyer has the corporate
power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. The execution and delivery
of this Agreement by Buyer and the consummation of the transactions contemplated hereby have been authorized. This Agreement has
been executed and delivered by Buyer and, assuming the due authorization, execution and delivery of this Agreement by Seller, constitutes
the legal and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, subject to applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors’ rights generally
from time to time in effect and to general principles of equity (including concepts of materiality, reasonableness, good faith
and fair dealing regardless) of whether considered in a proceeding in equity or at law.

 

Consents; Notices; No Violations,
Etc.

 

The execution and delivery
of this Agreement do not, and the consummation of the transactions contemplated hereby and the compliance with the terms hereof
will not: (i) violate any Governmental Rule, (ii) conflict with any provision of the certificate of incorporation or by-laws of
Buyer, (iii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default
(or give rise to any right of termination, cancellation or acceleration) under, or result in the creation of any Encumbrance upon
any of the Purchased Assets (other than those imposed by the Security Agreement) under any of the terms, conditions or provisions
of, any contract, agreement, plan, understanding, undertaking, commitment or arrangement, whether written or oral, any, note, bond,
mortgage, indenture, lease, license, deed of trust, loan, or other agreement, instrument or obligation to which Buyer is a party
or (iv) require any approval, authorization, consent, license, exemption, filing or registration with any court, arbitrator or
Governmental Entity, except with respect to the foregoing clauses (i) and (iii), for such violations or conflicts which would not
materially interfere with Buyer’s performance of its obligations hereunder or, with respect to the foregoing clause (iv),
for such approvals, authorizations, consents, licenses, exemptions, filings or registrations which have been obtained or made or
which, if not obtained or made, would not materially interfere with Buyer’s performance of its obligations hereunder.

 

Litigation

 

As of the date hereof,
there is no suit, claim, action, investigation or proceeding pending or, to the knowledge of Buyer, threatened against Buyer or
any of its Affiliates which if adversely determined would delay the ability of Buyer to perform any of its obligations hereunder.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 9 -	Confidential

     

    

 

Status of ANDAs

 

Buyer has reviewed each
of the ANDAs, recognizes that they may be subject to additional scrutiny by the FDA as a result of the Consent Decree, and recognizes
and assumes all risks and costs directly or indirectly associated with the ANDAs, obtaining FDA approval to transfer the manufacturing
site for the ANDAs and the Products.

 

Assumption of Regulatory Commitments

 

From and after the Closing
Date, Buyer will assume control of and responsibility for all costs, obligations and Liabilities arising from or related to, any
commitments or obligations to any Governmental Entity involving the ANDAs and any of the other Purchased Assets.

 

OTHER AGREEMENTS

 

Confidentiality

 

The parties agree that
the exchange of confidential information and materials relating to the Purchased Assets and the terms and conditions contained
in this Agreement shall be governed by the Mutual Confidential Disclosure Agreement, which is hereby incorporated herein by reference
in its entirety.  The term of the Mutual Confidential Disclosure Agreement is hereby extended by the parties for five (5)
years beyond the term of the Agreement.

 

Transfer of ANDAs and Technology
Transfer Assistance

 

For a period of 30 days
from and after the Closing Date, Seller will cooperate with Buyer in disclosing and copying any relevant records and reports which
are required to be made, maintained and reported pursuant to Governmental Rules in the Territory with respect to the ANDA that
is a part of the Purchased Assets, including ANDA documents, marketing and regulatory authorizations and a tech-transfer package
containing analytical methods, master batch records, validation reports, Annual Product Reports, finished product and raw material
specifications, and retain samples, in each case to the extent they are available. The Parties will make reasonable efforts to
recover any missing regulatory documents (original ANDA and any amendments or supplements thereto) from FDA and to take any other
actions required by the FDA to effect the transactions contemplated herein.

 

Intentionally left blank.

 

Further Action; Consents; Filings

 

Upon the terms and subject
to the conditions hereof, Seller and Buyer will use their respective reasonable efforts to: (i) take, or cause to be taken, all
actions necessary and proper under applicable Governmental Rules or otherwise to satisfy the conditions to Closing and consummate
and make effective the transactions contemplated by this Agreement, (ii) obtain from the requisite Governmental Entities any consents,
licenses, permits, waivers, approvals, authorizations or orders required to be obtained or made in connection with the authorization,
execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement, and (iii) make
all necessary filings, and thereafter make any other advisable submissions, with respect to this Agreement and the transactions
contemplated by this Agreement required under any applicable Governmental Rules. The parties will cooperate with each other in
connection with the making of all filings, including by providing all such non-confidential documents to the other party hereto
and its advisors prior to filing and, if requested, by accepting all reasonable additions, deletions or changes suggested in connection
therewith. Seller and Buyer will furnish all information required for any application or other filing to be made pursuant to the
rules and regulations of any applicable Governmental Rules in connection with the transactions contemplated by this Agreement.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 10 -	Confidential

     

    

 

TERMINATION AMENDMENT AND WAIVER

 

Termination

 

(a)          This
Agreement may be terminated and the transactions contemplated hereby abandoned at any time prior to the Closing:

 

		(i)	by mutual written consent of Seller and Buyer; or

 

		(ii)	by Buyer if any of the conditions set forth in Section 3.3 will have become incapable of
fulfillment and will not have been waived by Buyer; or

 

		(iii)	by Seller if any of the conditions set forth in Section 3.4 will have become incapable of
fulfillment and will not have been waived by Seller,

 

provided, the party seeking termination pursuant
to clause (ii) or (iii) is not in breach of any of its representations, warranties, covenants or agreements contained in this Agreement.

 

(b)         In
the event of termination of this Agreement by either party pursuant to this Section, written notice thereof will be given to the
other party and the transactions contemplated by this Agreement will be terminated, without further action by either party. If
this Agreement is terminated as provided herein:

 

		(i)	Buyer will return the Purchased Assets and all documents and other material received from Seller
relating to the Purchased Assets and to the transactions contemplated hereby, whether so obtained before or after the execution
hereof, to Seller; and

 

		(ii)	All confidential information received by Buyer with respect to Seller, the Purchased Assets will
be continued to be treated confidential in accordance with the Mutual Confidential Disclosure Agreement.

 

Amendments and Waivers

 

This Agreement may not
be amended except by an instrument in writing signed by both parties hereto. By an instrument in writing, Buyer, on the one hand,
or Seller, on the other hand, may waive compliance by the other party with any term or provision of this Agreement that such other
party was or is obligated to comply with perform.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 11 -	Confidential

     

    

 

INDEMNIFICATION

Survival

 

All representations and
warranties of Seller and Buyer contained herein or made pursuant hereto will survive the Closing Date for an indefinite period
or until such time as Buyer and Seller shall mutually agree in writing. The covenants and agreements of the parties hereto contained
in this Agreement will survive and remain in full force for the applicable periods described herein or, if no such period is specified,
indefinitely. Any right of indemnification pursuant to this Article with respect to a claimed breach of a representation, warranty,
covenant, agreement or obligation shall expire only upon written release by the party whom such representation, warranty, covenant,
agreement or obligation is owed. The provisions of this Section 8.1 will survive for so long as any other Section of this
Agreement will survive.

 

Indemnification

 

(a)         Seller
Indemnification. Seller hereby agrees to indemnify and defend Buyer and its Affiliates, and their respective officers, directors
and employees (the “Buyer Indemnified Parties”) against, and agrees to hold them harmless from, any Losses to
the extent such Losses arise from or in connection with the following:

 

(i)           breach
or alleged breach by Seller and/or any of its Affiliates or successors in interest thereto of any representation or warranty made
by it contained in this Agreement;

 

(ii)          any
breach or alleged breach by Seller and/or any of its Affiliates or successors in interest thereto of any of its covenants, agreements
or obligations contained in this Agreement; or

 

(iii)         events,
conditions actions or circumstances arising prior to the Closing;

 

provided, that Seller’s aggregate liability
in respect of all Losses suffered or incurred by Buyer Indemnified Parties shall not exceed, and Seller will have no obligation
to compensate any Buyer Indemnified Party for Losses in excess of, an aggregate amount equal to the Purchase Price. Seller may
satisfy any obligation hereunder to compensate Buyer Indemnified Parties by a reduction in the unpaid balance of the Purchase Note;
and, if the amount of such Losses exceeds the unpaid portion of the Purchase Note, then, to the extent that any portion of the
Purchase Price or the payments due on the Purchase Note have been paid in the form of shares of stock in Buyer, Seller may pay
such excess Losses with shares of common stock in Buyer. If Seller elects to use common stock in Buyer to compensate the excess
Losses suffered or incurred by the Buyer Indemnified Parties, then the value of each share shall be the average closing price of
a share of Buyer’s common stock on the principal trading market on which such shares are then trading for the 10 trading
days immediately preceding the date on which the shares are delivered in payment.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 12 -	Confidential

     

    

 

(b)         Buyer
Indemnification. Buyer hereby agrees to indemnify and defend Seller and its Affiliates and related companies, and their respective
officers, directors and employees (the “Seller Indemnified Parties”) against, and agrees to hold them harmless
from, any Losses to the extent such Losses arise from or in connection with the following:

 

(i)           any
breach or alleged breach by Buyer and/or any of its Affiliates or successors in interest of any representation or warranty made
by it contained in this Agreement;

 

(ii)          any
breach or alleged breach by Buyer and/or any of its Affiliates or successors in interest of any of its covenants, agreements or
obligations contained in this Agreement; or

 

(iii)         any
and all liability in connection with the use and sale of the Product(s) by Buyer or the ANDAs

 

provided, that Buyer’s aggregate liability
in respect of all Losses suffered or incurred by Seller Indemnified Parties shall not exceed, and Buyer will have no obligation
to compensate any Seller Indemnified Party for Losses in excess of, an aggregate amount equal to the Purchase Price.

 

Procedure

 

In order for an Indemnified
Party under this Article 8 (an “Indemnified Party”) to be entitled to any indemnification provided for
under this Agreement, the Indemnified Party will, within a reasonable period of time following the discovery of the matters giving
rise to any Losses, notify its applicable insurer and the indemnifying party under this Article 8 (the “Indemnifying
Party”) in writing of its claim for indemnification for such Losses, specifying in reasonable detail the nature of the
Losses and the amount of the liability estimated to accrue therefrom; provided, however, that failure to give notification
will not affect the indemnification provided hereunder, except to the extent the Indemnifying Party will have been actually prejudiced
as a result of the failure. Thereafter, the Indemnified Party will deliver to the Indemnifying Party, within a reasonable period
of time after the Indemnified Party’s receipt of such request, all information, records and documentation reasonably requested
by the Indemnifying Party with respect to such Losses. The Indemnifying Party shall control all litigation reflecting to the indemnification.
Without limiting the foregoing, the Indemnified Party shall control choice of counsel, staffing, and all decisions to be made with
the litigation.

 

If the indemnification sought
pursuant hereto involves a claim made by a non-party against the Indemnified Party (a “Non-Party Claim”), the
Indemnifying Party will be entitled to participate in the defense of such Non-Party Claim and, if it so chooses, to assume the
defense of such Non-Party Claim with counsel selected by the Indemnifying Party. Should the Indemnifying Party so elect to assume
the defense of a Non-Party Claim, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses subsequently
incurred by the Indemnified Party in connection with the defense thereof. If the Indemnifying Party assumes such defense, the Indemnifying
Party will control such defense. The Indemnifying Party will be liable for the reasonable fees and expenses of counsel employed
by the Indemnified Party for any period during which the Indemnifying Party has not assumed the defense thereof (other than during
any period in which the Indemnified Party will have failed to give notice of the Non-Party Claim as provided above). If the Indemnifying
Party chooses to defend or prosecute a Non-Party Claim, all of the parties hereto will cooperate in the defense or prosecution
thereof. Such cooperation will include the retention and (upon the Indemnifying Party’s request) the provision to the Indemnifying
Party of records and information, which are reasonably relevant to such Non-Party Claim, and making employees available on a mutually
convenient basis to provide additional information and explanation of any material provided hereunder. If the Indemnifying Party
chooses to defend or prosecute any Non-Party Claim, the Indemnifying Party will seek the approval of the Indemnified Party (not
to be unreasonably withheld) to any settlement, compromise or discharge of such Non-Party Claim the Indemnifying Party may recommend
and which by its terms obligates the Indemnifying Party to pay the full amount of the liability in connection with such Non-Party
Claim. Whether or not the Indemnifying Party will have assumed the defense of a Non-Party Claim, the Indemnified Party will not
admit any liability with respect to, or settle, compromise or discharge, such Non-Party Claim without the Indemnifying Party’s
prior written consent. The Indemnifying Party shall reimburse upon demand, all reasonable costs and expenses incurred by the Indemnified
Party in cooperation with the defense or prosecution of the Non-Party Claim.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 13 -	Confidential

     

    

 

Exclusive Remedy.

 

The indemnification rights
provided in this Article 8 shall constitute the sole and exclusive remedy with respect to all claims of any kind or nature related
to, or arising out of, or in connection with, any breach of or inaccuracy in any representation, warranty or covenant contained
in this Agreement (other than claims arising from fraud or intentional misrepresentation on the part of a party in connection with
the transactions contemplated by this Agreement). Nothing in this Section 8.4 shall limit any party's right to seek and obtain
any equitable relief, including specific performance, to which any party shall be entitled or to seek any remedy on account of
any party's fraudulent or intentional misrepresentation.

 

GENERAL PROVISIONS

 

Expenses

 

Except as otherwise specified
in this Agreement, all costs and expenses, including fees and disbursements of counsel, financial advisors and accountants, incurred
in connection with this Agreement and the transactions contemplated hereby will be paid by the party incurring such costs and expenses,
whether or not the Closing will have occurred.

 

Further Assurances and Actions

 

Each of the parties hereto,
upon the request of the other party hereto, whether before or after the Closing and without further consideration, will do, execute,
acknowledge and deliver or cause to be done, executed, acknowledged or delivered all such further acts, deeds, documents, assignments,
transfers, conveyances, powers of attorney and assurances as may be reasonably necessary to effect complete consummation of the
transactions contemplated by this Agreement. Seller and Buyer agree to execute and deliver such other documents, certificates,
agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement
expeditiously the transactions contemplated by this Agreement.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 14 -	Confidential

     

    

 

Notices

 

All notices and other communications
required or permitted to be given or made pursuant to this Agreement shall be in writing signed by the sender and shall be deemed
duly given: (a) on the date delivered, if personally delivered, (b) on the date sent by facsimile with automatic confirmation by
the transmitting machine showing the proper number of pages were transmitted without error, (c) on the Business Day after being
sent by Federal Express or another recognized overnight mail service which utilizes a written form of receipt for next day or next
business day delivery, or (d) upon receipt after mailing, if mailed by United States postage-prepaid certified or registered mail,
return receipt requested, in each case addressed to the applicable party at the address set forth below: provided that a
party may change its address for receiving notice by the proper giving of notice hereunder:

 

		(a)	if to Seller, to:

 

Mikah Pharma LLC

20 Kilmer Drive

Hillsborough, New Jersey, 08844

Attention: Nasrat Hakim, President

Fax No.: (908) 450-1318

 

		(b)	if to Buyer, to:

 

Elite Laboratories, Inc.

165 Ludlow Avenue

Northvale, New Jersey 0764760

Attn: Jerry Treppel

Fax No.: (201) 750-2755

 

With a courtesy copy, which shall not constitute notice
hereunder, sent to:

 

Richard Feiner, Esq.

381 Park Avenue South

16th floor

New York, NY 10016

Attn: Richard Feiner

Fax No.: (917) 720-0863

 

Headings

 

The table of contents and
headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation
of this Agreement.

 

Severability

 

If any term or other provision
of this Agreement is invalid, illegal or incapable of being enforced under any law or public policy, all other terms and provisions
of this Agreement will nevertheless remain in full force and effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the parties hereto will negotiate in good faith to modify this Agreement
so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner in order that the transactions
contemplated hereby are consummated as originally contemplated to the greatest extent possible.

 

{***} Confidential portions
of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

    		- 15 -	Confidential

     

    

 

Counterparts

 

This Agreement may be executed
in one (1) or more counterparts, all of which will be considered one and the same agreement and will become effective when one
or more counterparts have been signed by each of the Parties hereto and delivered to the other parties hereto. This Agreement,
once executed by a Party, may be delivered to the other Party hereto by facsimile or electronic transmission of a copy of this
Agreement bearing the signature of the Party so delivering this Agreement. A faxed or electronically delivered signature shall
have the same legally binding effect as an original signature.

 

Entire Agreement: No Non-Party
Beneficiaries

 

This Agreement and the
Exhibits and Schedules hereto constitute the entire agreement and supersede all prior agreements and understandings both written
and oral (including any letter or intent, memorandum of understanding electronic communicators, e-mail or term sheet), between
or among the parties hereto with respect to the subject matter hereof. Except as specifically provided herein or therein, such
agreements are not intended to confer upon any non-party other than the parties hereto any rights or remedies hereunder or thereunder.

 

Governing Law

 

This Agreement and any
and all matters arising directly or indirectly herefrom shall be governed by and construed and enforced in accordance with the
laws of the State of New Jersey, U.S.A. applicable to agreements made and to be performed entirely in such state, without giving
effect to the conflict of law principles thereof.

 

Jurisdiction, Venue, Service
of Process

 

Buyer and Seller agree
to irrevocably submit to the sole and exclusive jurisdiction of the state or federal courts in the state of New Jersey for any
suit, action or other proceeding arising out of this Agreement or any transaction contemplated hereby. Notwithstanding the foregoing,
only if such suit, action or other proceeding may not be brought in New Jersey, it may instead be brought in a Delaware court of
appropriate jurisdiction. Each party agrees that service of any process, summons, notice or document by U.S. registered mail or
recognized international courier service to such party’s address set forth in this Agreement shall be effective service of
process.

 

Specific Performance

 

The parties hereto agree
that irreparable damage would occur in the event any provision of this Agreement were not performed in accordance with the terms
hereof and that the parties will be entitled to specific performance of the terms hereof, in addition to any other remedy at law
or in equity, without the necessity of demonstrating the inadequacy of monetary damages and without the posting of a bond.

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 16 -	Confidential

     

    

 

Force Majeure

 

Neither party will be in
default of this Agreement to the extent that performance of its obligations (other than obligations to pay amounts owed under this
Agreement) is delayed or prevented by reason of events or circumstances beyond its reasonable control, including without limitation,
earthquake, flood or other acts of God, fire, explosion, terrorism, war, compliance with laws, regulations or governmental or judicial
orders, labor disputes, unavailability of transportation (“Force Majeure”). Should either party be delayed in
or prevented from performing any of its obligations under this Agreement by reason of Force Majeure, such party shall give prompt
notice thereof to the other party and shall be obligated to perform the affected obligations within sixty (60) days after the Force
Majeure ceases to delay or prevent performance thereof.

 

Publicity

 

Neither party will make
any public announcement concerning, or otherwise publicly disclose, any information with respect to the transactions contemplated
by this Agreement or any of the terms and conditions hereof without the prior written consent of the other parties hereto. Notwithstanding
the foregoing, either party may make any public disclosure concerning the transactions contemplated hereby that in the opinion
of such party’s counsel may be required by law or the rules of any stock exchange on which such party’s or its Affiliates’
securities trade; provided, however, the party making such disclosure will provide the non-disclosing party with
a copy of the intended disclosure reasonably, and to the extent practicable, prior to public dissemination, and the parties hereto
will coordinate with one another regarding the timing, form and content of such disclosure. Notwithstanding the foregoing, after
the Closing, Buyer may publicize its ability to market and sell the Product(s) without approval from Seller.

 

Schedules and Exhibits.

 

The Schedules and all Exhibits
attached hereto are hereby incorporated by reference into, and made a part of, this Agreement.

 

Ambiguities.

 

Each Party and its counsel
have participated fully in the review and revision of this Agreement. Any rule of construction to the effect that ambiguities are
to be resolved against the drafting party shall not apply in interpreting this Agreement. The language in this Agreement shall
be interpreted as to its fair meaning and not strictly for or against any Party.

 

Assignment

 

Neither party may assign
its rights or obligations under this Agreement without the prior written consent of the other party; provided, however,
that either party may assign its rights and obligations under this Agreement, without the prior written consent of the other party,
to an Affiliate or to a successor of the assignment party by reason of merger, sale of all or substantially all of its assets or
any similar transaction. Any permitted assignee or successor-in-interest will assume all obligations of its assignor under this
Agreement. No assignment will relieve either party of its responsibility for the performance of any obligation. This Agreement
will be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

[signature page follows]

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 17 -	Confidential

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be signed by their respective representatives thereunto duly authorized, all as
of the date first written above.

 

	 	   MIKAH PHARMA LLC	 	 	ELITE LABORATORIES, INC.
	 	 	 	 	 
	By:	s/Nasrat Hakim	 	By:	s/Jerry Treppel
	 	Nasrat Hakim, President and CEO	 	 	Jerry Treppel, Chief Executive Officer

 

{***} Confidential portions of this exhibit
have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

    		- 18 -	Confidential

     

    

 

SCHEDULE 1

 

ABBREVIATED NEW DRUG APPLICATIONS

 

 

	Number	 	Description	 	Status
	 	 	 	 	 
	77-169	 	Isradipine Capsules USP, 2.5 and 5 mg	 	Approved ANDA
	 	 	 	 	 
	40-762	 	Phendimetrazine Tartrate Tablets USP, 35 mg	 	Approved ANDA
	 	 	 	 	 
	{***}	 	{***}	 	Approved ANDA
	 	 	 	 	 
	{***}	 	{***}	 	Approved ANDA
	 	 	 	 	 
	{***}	 	{***}	 	Approved ANDA
	 	 	 	 	 
	{***}	 	{***}	 	Approved ANDA
	 	 	 	 	 
	{***}	 	{***}	 	Approved ANDA
	 	 	 	 	 
	76-868	 	Loxapine Capsules, 5 mg, 10 mg, 25 mg and 50 mg	 	Approved ANDA
	 	 	 	 	 
	76-686	 	Dantrolene Sodium Capsules, 25 mg, 50 mg, and 100 mg	 	Approved ANDA
	 	 	 	 	 
	40-600	 	Hydroxyzine Tablets, 10 mg	 	Approved ANDA
	 	 	 	 	 
	40-602	 	Hydroxyzine Tablets, 25 mg	 	Approved ANDA
	 	 	 	 	 
	40-604	 	Hydroxyzine Tablets, 50 mg	 	Approved ANDA
	 	 	 	 	 
	Pending:	 	 	 	 
	 	 	 	 	 
	40-830	 	Acetaminophen, Caffeine, Dihydrocodeine Bitartrate Capsules, 356.4 mg/30 mg/16 mg	 	Pending ANDA

 

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 1 -	Confidential

     

    

  

EXHIBIT A

 

BILL OF SALE

 

THIS BILL OF SALE, dated
August 1, 2013, is executed by Mikah Pharma LLC (“Seller”), a limited liability company organized under the laws of
Delaware in favor of Elite Laboratories, Inc. (“Buyer”), a corporation incorporated under the laws of Delaware, pursuant
to the Asset Purchase Agreement, dated August 1, 2013 (the “Agreement”), by and between Seller and Buyer. Capitalized
terms used but not defined herein have the meanings given to them in the Agreement.

 

i.            The
Agreement provides for, among other things, the sale of the Purchased Assets by Seller to Buyer.

 

ii.           In
consideration of the payment of the amounts set forth in the Agreement, Seller by this Bill of Sale does hereby, sell, transfer,
assign and deliver to Buyer, all of its rights, title and interest in and to the Purchased Assets.

 

iii.          Seller
hereby represents that from time to time after the delivery of this instrument, at Buyer’s request and without further consideration,
Seller will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further
acts, deeds, conveyances, transfers, assignments, powers of attorney and assurances as reasonably may be required more effectively
to convey, transfer to and vest in Buyer, and to put Buyer in possession of, the Purchased Assets.

 

iv.          This
instrument is executed by, and will be binding upon, Seller and its successors and assigns for the uses and purposes set forth
herein.

 

v.           This
Bill of Sale shall be construed and enforced in accordance with the laws of the State of New Jersey.

 

IN WITNESS WHEREOF,
this Bill of Sale has been duly executed and delivered by Seller as of the date and year first written above.

 

	 	 MIKAH PHARMA LLC	 
	 	 	 
	By:	s/Nasrat Hakim	 
	 	Nasrat Hakim, President and CEO	 

 

 

{***} Confidential portions of this exhibit
have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

    		- 1 -	Confidential

     

    

  

EXHIBIT B

 

FORM OF SECURED CONVERTIBLE PROMISSORY
NOTE

 

Filed with the Company’s Form 8-K (filed with the Commission
on August 5, 2013) as Exhibits 10.2.

 

 

{***} Confidential portions of this exhibit
have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

    		- 1 -	Confidential

     

    

 

EXHIBIT C

 

FORM OF ANDA SECURITY AGREEMENT

 

Filed with the Company’s Form 8-K
(filed with the Commission on August 5, 2013) as 10.3.

 

 

{***} Confidential portions of this exhibit have been redacted
and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

 

    		- 2 -	Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]